2023-11-14T17:46:30-06:00 2022-12-31 ERNST & YOUNG US LLP 111 MONUMENT CIRCLE SUITE 4000 INDIANAPOLIS IN 46204 990 2022-01-01 912154267 Memorial Sloan-Kettering Cancer Center % KEVIN MALARKEY MEMO 6462273092 1275 York Avenue New York NY 10065 MICHAEL HARRINGTON EVP & CFO 6462273722 2023-11-13 true MICHAEL HARRINGTON 999009999 JENNIFER D RHODERICK P00395735 3176817000 2023-11-13 2 2022 2023-04-26 12:10:37Z SELWYN M VICKERS MD 1275 York Avenue New York NY 10065 8031562034 true true 3475 X www.mskcc.org X LEADERSHIP IN THE PREVENTION, TREATMENT, AND CURE OF CANCER THROUGH EXCELLENCE, VISION , AND COST EFFECTIVENESS IN PATIENT CARE, OUTREACH PROGRAMS, RESEARCH, AND EDUCATION. 116 105 25794 438 11602554 817480000 693029020 5422024000 5673295000 534488000 808719000 156818000 76903980 6930810000 7251947000 21438500 18006000 0 0 3314805014 3626916179 0 0 85128654 2808113486 3207084821 6144357000 6852007000 786453000 399940000 14941252000 13998385000 5116410000 5257167000 9824842000 8741218000 X THE MISSION OF MEMORIAL SLOAN-KETTERING CANCER CENTER IS TO LEAD IN THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF CANCER AND ASSOCIATED DISEASES THROUGH PROGRAMS OF EXCELLENCE IN RESEARCH, EDUCATION, OUTREACH AND COST-EFFECTIVE PATIENT CARE. LEADERSHIP IN PATIENT CARE: WE PLACE THE HIGHEST PRIORITY ON ADVANCING THE CARE OF CANCER PATIENTS THROUGH EARLY DETECTION, ACCURATE DIAGNOSIS, AND OPTIMAL TREATMENT. THESE THREE ELEMENTS LEAD TO THE MOST EFFECTIVE CANCER CARE POSSIBLE, WHICH IS ALSO THE MOST COST-EFFECTIVE CARE. WE STRIVE FOR EXCELLENCE IN ALL EXISTING AND EMERGING THERAPIES WITHOUT NEGLECTING THE NEED FOR ADVANCED APPROACHES IN PALLIATION. WE DELIVER THESE THERAPIES IN A CARING ENVIRONMENT THAT ENCOMPASSES PATIENTS AS WELL AS THEIR LOVED ONES. EXCELLENCE IN PATIENT CARE IS EXEMPLIFIED BY OUR MULTIDISCIPLINARY APPROACH, A CORE COMPETENCE OF OUR CENTER. WE ARE COMMITTED TO DEVELOPING OUTREACH PROGRAMS TO BRING EXCELLENCE IN CANCER CARE TO THE COMMUNITY. LEADERSHIP IN RESEARCH EX false false 5536139759 6838000 5487374000 PATIENT CARE: MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERTS HAVE ESTABLISHED STANDARDS OF CARE AND TREATMENT PROTOCOLS FOR EACH TYPE AND STAGE OF CANCER. OUR PHYSICIANS HAVE AN EXTRAORDINARY DEPTH AND BREADTH OF EXPERIENCE IN DIAGNOSING AND TREATING ALL FORMS OF THE DISEASE, FROM THE MOST COMMON TO THE VERY RARE. EACH YEAR, THEY TREAT MORE THAN 400 DIFFERENT SUBTYPES OF CANCER. THIS LEVEL OF SPECIALIZATION CAN HAVE AN OFTEN-DRAMATIC EFFECT ON A PATIENT'S CHANCES FOR A CURE OR CONTROL OF THEIR CANCER. WHILE WE ARE KNOWN FOR OUR ADVANCED, INNOVATIVE THERAPIES, OUR PHYSICIANS ARE EQUALLY WELL REGARDED FOR THEIR COMPASSION AND CONCERN. OUR DISEASE MANAGEMENT PROGRAM FEATURES 16 MULTIDISCIPLINARY CANCER TEAMS. PATIENTS ARE TREATED BY AS MANY DIFFERENT SPECIALISTS AS ARE NEEDED FOR THEIR PARTICULAR TYPE OF DISEASE, INCLUDING SURGEONS, MEDICAL ONCOLOGISTS, RADIATION ONCOLOGISTS, RADIOLOGISTS, PATHOLOGISTS, PSYCHIATRISTS, AND NURSES. OUR PATHOLOGISTS HAVE UNSURPASSED EXPERTISE IN USING ADVANCED METHODS TO ACCURATELY DIAGNOSE CANCER. BECAUSE OF THEIR SOLE FOCUS ON CANCER, OUR SURGEONS USE SURGICAL TECHNIQUES THAT PRESERVE FORM AND FUNCTION. OUR RADIATION ONCOLOGISTS ARE DEVELOPING AND PUTTING INTO CLINICAL PRACTICE LEADING-EDGE TECHNOLOGIES AND TECHNIQUES IN RADIATION THERAPY. IN ADDITION, THE CENTER OFFERS A FULL RANGE OF PROGRAMS TO HELP PATIENTS AND FAMILIES THROUGHOUT ALL PHASES OF TREATMENT, INCLUDING SUPPORT GROUPS, GENETIC COUNSELING, HELP MANAGING CANCER PAIN AND SYMPTOMS, REHABILITATION, INTEGRATIVE MEDICINE SERVICES, AND ASSISTANCE IN NAVIGATING LIFE AFTER TREATMENT. THROUGHOUT THE COVID-19 PANDEMIC AND BEYOND MSKCC CONTINUES TO WORK TO PROTECT AND ASSIST THE PUBLIC. CURRENTLY, THE INSTITUTION IS ACTIVELY MAINTAINING A POSTURE OF PREVENTION AND SAFETY, WITH ITS EDUCATION PROGRAMS WHILE ENCOURAGING PERSONS TO WEAR THEIR MASKS AND ADHERE TO OTHER PREVENTIVE MEASURES LIKE GETTING BOOSTER SHOTS. 929342368 9419000 185921000 RESEARCH: MEMORIAL SLOAN-KETTERING CANCER CENTER MAINTAINS ONE OF THE WORLD'S MOST DYNAMIC PROGRAMS OF CANCER RESEARCH. THE EXTRAORDINARY PATIENT CARE WE PROVIDE BENEFITS FROM OUR INNOVATIVE PROGRAMS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH. RESEARCH AT SLOAN-KETTERING INSTITUTE IS DEDICATED TO UNDERSTANDING THE BIOLOGY OF CANCER THROUGH PROGRAMS IN CELL BIOLOGY, GENETICS, BIOCHEMISTRY, MOLECULAR BIOLOGY, STRUCTURAL BIOLOGY, COMPUTATIONAL BIOLOGY, IMMUNOLOGY, AND THERAPEUTICS. INVESTIGATORS AT SLOAN-KETTERING INSTITUTE COLLABORATE WITH MEMORIAL HOSPITAL PHYSICIAN-SCIENTISTS, A PARTNERSHIP THAT HELPS SPEED IMPORTANT RESEARCH FINDINGS FROM THE LABORATORY TO THE BEDSIDE, IN A PROCESS KNOWN AS TRANSLATIONAL RESEARCH. MEMORIAL SLOAN-KETTERING CANCER CENTER ALSO ACTIVELY INITIATES AND PARTICIPATES IN CLINICAL TRIALS TO IDENTIFY MORE EFFECTIVE CANCER THERAPIES, AND OUR PHYSICIANS ARE CURRENTLY LEADING MORE THAN 1,900 CLINICAL TRIALS FOR PEDIATRIC AND ADULT CANCERS. THE HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM (HOPP) IS A FURTHER EFFORT TO INCREASE INSTITUTIONAL RESEARCH STRENGTH IN AREAS IMPORTANT IN CONTEMPORARY TRANSLATIONAL RESEARCH. HOPP IS DESIGNED TO MELD EVEN MORE THOROUGHLY THE CULTURES OF BASIC BIOLOGIC SCIENCE AND CLINICAL ONCOLOGY, AUGMENTING THE WORK CONDUCTED IN THE LABORATORIES OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S PHYSICIAN-SCIENTISTS. 237089883 1749000 EDUCATION: EDUCATION IS A VITAL PART OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S MISSION. OUR TRAINING PROGRAMS PREPARE PHYSICIANS AND SCIENTISTS FOR CAREERS IN THE BIOMEDICAL SCIENCES. OUR COLLABORATIONS WITH THE ROCKEFELLER UNIVERSITY, CORNELL UNIVERSITY, AND WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY OFFER PHD PROGRAMS IN CHEMICAL BIOLOGY, COMPUTATIONAL BIOLOGY AND MEDICINE, AND THE MEDICAL SCIENCES. THE CENTER ALSO PARTNERS WITH WEILL MEDICAL COLLEGE AND THE ROCKEFELLER UNIVERSITY TO OFFER A MD/PHD DEGREE FOR ASPIRING PHYSICIAN-SCIENTISTS. THE CENTER HAS A PHD PROGRAM IN CANCER BIOLOGY THROUGH ITS LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES. THIS NOVEL PROGRAM HAS BEEN ENROLLING STUDENTS SINCE 2006 AND TRAINS BASIC LABORATORY SCIENTISTS TO WORK IN RESEARCH AREAS DIRECTLY RELEVANT TO CANCER AND OTHER HUMAN DISEASES. WE ALSO OFFER POSTGRADUATE CLINICAL FELLOWSHIPS TO TRAIN PHYSICIANS WHO SEEK SPECIAL EXPERTISE IN A PARTICULAR TYPE OF CANCER AND POSTGRADUATE RESEARCH FELLOWSHIPS THAT PROVIDE PHYSICIANS AND SCIENTISTS WITH ADVANCED LABORATORY RESEARCH TRAINING. WITH FACULTY APPOINTMENTS AT THE WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, OUR CLINICAL STAFF ALSO TRAIN RESIDENTS AND MEDICAL STUDENTS. 6702572010 true true false true false false false false false true true true false false true false false true true true true false false false true false true true true true true true false false false false false true false false true true true false false false true true true true false false true 1399 0 true 25794 true true true false false false false true true false false false false true false X 116 105 true false false false true true false true true false false true true true true true true true true false AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY X X KEVIN MALARKEY 6462272638 1275 YORK AVENUE NEW YORK NY 100656007 X CRAIG B THOMPSON MD PRESIDENT & CEO-UNTIL 9/22 50.0 0.0 X X 7914850 0 206110 JASON KLEIN SVP CHIEF INVESTMENT OFFICER 50.0 0.0 X 6807925 0 76122 MARK BILSKY MD ATTENDING-NEUROSURGERY 50.0 0.0 X 3351870 0 60126 BABAK MEHRARA MD CHIEF ATTENDING-SURGERY 50.0 0.0 X 2771948 0 73619 MICHAEL HARRINGTON EVP & CFO 50.0 0.0 X X 2743280 0 58995 JULIO GARCIA AGUILAR MD CHIEF ATTENDING-SURGERY 50.0 0.0 X 2727893 0 73626 JEFFREY DREBIN MD CHAIRMAN ATTENDNING-SURGERY 50.0 0.0 X 2721892 0 75744 KATHRYN MARTIN EVP & COO 50.0 0.0 X X 2433536 0 72953 MARTIN WEISER MD ATTENDING-SURGERY 50.0 0.0 X 2400313 0 77331 LISA DEANGELIS MD PHYSICAN IN CHIEF 50.0 0.0 X 2153086 0 71882 SIMON POWELL MD DIRECTOR MSKCC PROTON, INC. 50.0 0.0 X 1982898 0 61212 JOAN MASSAGUE PHD DIRECTOR 50.0 0.0 X 1799890 0 70264 KENNETH MANOTTI SVP DEVELOPMENT 50.0 0.0 X 1530627 0 66002 JORGE LOPEZ ESQ EVP GENERAL COUNSEL 50.0 0.0 X 1517979 0 76896 SELWYN VICKERS MD PRESIDENT & CEO EFF 9/22 50.0 0.0 X X 1366363 0 59052 ROXANNE TAYLOR SVP CHIEF MKT/COMM UNTIL 10/22 50.0 0.0 X 1359028 0 32394 DEBRA BERNS ESQ SVP CHIEF RISK OFFICER 50.0 0.0 X X 1273673 0 43731 KERRY BESSEY SVP CHIEF HR OFFICER 50.0 0.0 X 1224934 0 76420 FREDERICK GROVES EVP HOSPITAL ADMINISTRATION 50.0 0.0 X 1055906 0 60743 REMY EVARD EVP & CHIEF DIGIT OFF EFF 1/22 50.0 0.0 X 974374 0 52056 MARK SVENNINGSON SVP FINANCE 50.0 0.0 X X 944682 0 60966 MARGARET BURKE DIRECTOR, MSKCC PROTON, INC. 50.0 0.0 X 831215 0 76482 ERIN MCDONOUGH SVP CH MKT/COMM OFF EFF 10/22 50.0 0.0 X 767961 0 41344 CAROLYN LEVINE ESQ DEPUTY GEN COUNSEL 50.0 0.0 X 571052 0 47037 AMADOR CENTENO SVP REAL ESTATE DEVLP EFF 7/22 50.0 0.0 X 382805 0 25626 RICHARD I BEATTIE SEE SCH O 6.0 0.0 X 0 0 0 IAN COOK SEE SCHEDULE O 5.0 0.0 X X 0 0 0 STANLEY F DRUCKENMILLER SEE SCHEDULE O 3.0 0.0 X 0 0 0 ANTHONY B EVNIN SEE SCHEDULE O 3.0 0.0 X 0 0 0 ROGER W FERGUSON SEE SCHEDULE O 3.0 0.0 X 0 0 0 HENRY A FERNANDEZ SEE SCHEDULE O 3.0 0.0 X 0 0 0 WILLIAM E FORD SEE SCHEDULE O 3.0 0.0 X 0 0 0 RICHARD N FOSTER SEE SCHEDULE O 3.0 0.0 X 0 0 0 STEPHEN FRIEDMAN SEE SCHEDULE O 3.0 0.0 X 0 0 0 ELLEN V FUTTER SEE SCHEDULE O 4.0 0.0 X 0 0 0 LOUIS V GERSTNER JR SEE SCHEDULE O 7.0 0.0 X X 0 0 0 JONATHAN N GRAYER SEE SCHEDULE O 3.0 0.0 X 0 0 0 BENJAMIN W HEINEMAN JR SEE SCHEDULE O 3.0 0.0 X 0 0 0 WILLIAM HELMAN SEE SCHEDULE O 3.0 0.0 X 0 0 0 JEFFREY P JOHNSON SEE SCHEDULE O 2.0 0.0 X 0 0 0 MARGARET KEANE SEE SCHEDULE O 3.0 0.0 X 0 0 0 MARIE-JOSEE KRAVIS SEE SCHEDULE O 6.0 0.0 X X 0 0 0 JAMIE C NICHOLLS SEE SCHEDULE O 5.0 0.0 X X 0 0 0 JAMES G NIVEN SEE SCHEDULE O 5.0 0.0 X 0 0 0 BRUCE C RATNER SEE SCHEDULE O 3.0 0.0 X 0 0 0 CLIFTON S ROBBINS SEE SCHEDULE O 4.0 0.0 X 0 0 0 ALEXANDER T ROBERTSON SEE SCHEDULE O 3.0 0.0 X 0 0 0 JAMES D ROBINSON III SEE SCHEDULE O 3.0 0.0 X 0 0 0 VIRGINIA M ROMETTY SEE SCHEDULE O 3.0 0.0 X 0 0 0 ALAN D SCHNITZER SEE SCHEDULE O 5.0 0.0 X 0 0 0 STEPHEN C SHERRILL SEE SCHEDULE O 5.0 0.0 X 0 0 0 PETER J SOLOMON SEE SCHEDULE O 3.0 0.0 X 0 0 0 JOHN R STRANGFELD SEE SCHEDULE O 3.0 0.0 X X 0 0 0 SCOTT M STUART SEE SCHEDULE O 7.0 0.0 X X 0 0 0 DOUGLAS A WARNER III SEE SCHEDULE O 5.0 0.0 X X 0 0 0 PETER A WEINBERG SEE SCHEDULE O 2.0 0.0 X X 0 0 0 53609980 0 1696733 10157 false true false JGN CONSTRUCTION CORP 66-40 69TH STREET MIDDLE VILLAGE NY 11379 GENERAL CONSTRUCTION 17994620 WORTHINGTON ENERGY 445 HUTCHINSON AVENUE COLUMBUS OH 43235 GENERAL CONSTRUCTION 12386154 LEND LEASE US CONSTRUCTION 200 PARK AVENUE NEW YORK NY 10166 GENERAL CONSTRUCTION 10176404 MICHAEL ANTHONY CONTRACTING 161 RAILROAD AVENUE NEW HYDE PARK NY 11040 GENERAL CONSTRUCTION 9760497 BOSTON CONSULTING GROUP 10 HUDSON YARDS NEW YORK NY 10001 CONSULTING 7575000 203 4668603 234270000 454090417 12032474 693029020 MEDICAL CARE 622310 5487374000 5487374000 NON-GOVERNMENT SPONSORED RESEARCH 541711 185921000 185921000 5673295000 101754000 -9140686 110894686 0 50886000 50886000 34530000 48914000 -14384000 0 -14384000 -14384000 1436750818 729785818 706965000 706965000 706965000 257980 4668603 915216 -657236 -657236 0 0 0 0 0 0 CAFETERIA 722212 5971000 5971000 VENDOR DISCOUNTS 561439 2402000 2402000 SERVICES PROVIDED 561439 8048000 8048000 24638216 20743240 3894976 41059216 7251947000 5673295000 11602554 874020426 190000 190000 17816000 17816000 0 0 53881298 43895802 8280809 1704687 339857 339857 2818671871 2774494764 9704701 34472406 171254434 167933714 1432337 1888383 403610015 395461980 1211891 6936144 179158704 175674177 1502993 1981534 0 16810050 13642953 3136479 30618 1296023 1161649 133545 829 829671 829671 0 10807219 10807219 127029471 117230332 1115844 8683295 37659039 34749079 183223 2726737 375152704 350047444 3836005 21269255 125452124 123770674 659825 1021625 6620867 6620867 197473541 177241484 20099050 133007 8963300 8669472 96198 197630 0 14307251 13414650 293324 599277 122812813 122812813 0 437223926 431739952 5144416 339558 20901923 20732878 14377 154668 PHARMACEUTICALS 1416883903 1416883903 MEDICAL/SURGICAL SUPPLIES 337014057 337014057 EXPENSES OFFSETTING REVENUE -49829216 -48914000 -915216 UBIT EXPENSE 43411 43411 -367256 -882162 -3389311 3904217 6852007000 6702572010 64306336 85128654 X 13332009 4685726 8646283 197290000 327081000 1324503000 1225430000 510406000 535537000 623746000 660791000 0 0 100000 0 55017000 76446000 126425000 127758000 456894000 624529000 9104634000 4586070000 4412330000 4518564000 4665943000 3596839000 2504522000 2238842000 8549000 0 0 0 55527000 66568000 14941252000 13998385000 1229458000 1088723000 0 0 0 0 2999605000 3265895000 0 0 0 0 153465000 115325000 0 0 733882000 787224000 5116410000 5257167000 X 8106650000 7056745000 1718192000 1684473000 9824842000 8741218000 14941252000 13998385000 X 399940000 -1613299000 129735000 X false true X true true true X X 4 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 131624182 4 true 0 0 MEMORIAL HOSPITAL FOR CANCER & ALLIED DISEASES 131624082 3 true 0 0 MEMORIAL SLOAN-KETTERING CANCER CENTER 131924236 3 true 0 0 LOUIS V GERSTNER JR GRADUATE SCHOOL OF BIOMEDICAL SCIENCES 202212588 2 true 0 0 4 0 0 591422434 468105011 446134773 790884000 693051939 2989598157 0 0 591422434 468105011 446134773 790884000 693051939 2989598157 142463179 2847134978 190676000 123653294 129384000 154206000 152633000 750552294 0 0 3740150451 20140473782 0.76123 0.77077 X true false false false false false false false false false false false false false false false true false false false false 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SUPPORTED ORGANIZATIONS SUPPORT FROM THE SUPPORTING ORGANIZATIONS RELATE PRINCIPALLY TO THE SHARING OF CERTAIN FACILITIES, EQUIPMENT, PERSONNEL COSTS, EDUCATION, INSURANCE AND ALLOCATIONS. AMOUNTS DUE TO OR DUE FROM AFFILIATES RESULTING FROM THESE SERVICES DO NOT BEAR INTEREST. SUPPORTING ORGANIZATIONS NAME OF SUPPORTING ORGANIZATION EIN TYPE S.K.I. REALTY 13-3389586 12a MSK INSURANCE US 83-0363317 12a MSKCC PROTON INC. 35-2397819 12a MSKCC PROPERTIES, LLC. 35-2464610 12a RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 423176 false true 406495 829671 false LOBBYING COSTS THE ORGANIZATION ENGAGES IN FEDERAL, STATE, AND LOCAL LOBBYING. THE CENTER'S FEDERAL LOBBYING EFFORT FOCUSES ON PATIENT CARE AND REIMBURSEMENT ISSUES. PATIENT CARE ADVOCACY INCLUDES ENSURING PATIENTS ARE ABLE TO ACCESS CLINICAL TRIALS AND CANCER HOSPITALS ARE ABLE TO EFFECTIVELY RESEARCH POTENTIAL TREATMENTS FOR CANCER AS WELL AS PREVENTATIVE AND PALLIATIVE MEASURES. THE CENTER ALSO SEEKS EQUITABLE REIMBURSEMENT FOR SERVICES RENDERED TO PATIENTS ENROLLED IN ENTITLEMENT PROGRAMS. FROM TIME TO TIME, THE CENTER WEIGHS IN ON OTHER FEDERAL LEGISLATION THAT IMPACTS CANCER CARE AND HOSPITALS IN GENERAL. THE CENTER'S STATE LOBBYING EFFORTS FOCUS ON ISSUES RELATING TO PATIENT CARE, PUBLIC HEALTH, AND HOSPITAL OPERATIONS. PATIENT CARE AND PUBLIC HEALTH ISSUES MAY INCLUDE ACCESS TO CARE AND CANCER PREVENTION AND SCREENING, INCLUDING AS PART OF STATE BUDGET LEGISLATION. OUR ADVOCACY ON HOSPITAL OPERATIONS CENTERS ON ISSUES RELATING TO PROFESSIONAL LICENSURE AND CONTINUING EDUCATION, SCOPE OF PRACTICE, HOSPITAL STAFFING, AND HEALTH AND SAFETY REQUIREMENTS. ON OCCASION, THE CENTER ENGAGES IN LOCAL LOBBYING ON ISSUES RANGING FROM BUILDING ORDINANCES TO RADIATION CONTROL. THE CENTER ALSO INCURS COSTS FOR FEDERAL, STATE, AND LOCAL LOBBYING BY ASSOCIATIONS AND OTHER ORGANIZATIONS OF WHICH IT IS A MEMBER. PART II-B LINE 1(I) OTHER ACTIVITIES LOBBYING PORTION OF DUES PAID IN 2022 GREATER NEW YORK HOSPITAL ASSOCIATION $ 279,443 AMERICAN HOSPITAL ASSOCIATION 39,234 HOSPITAL ASSOC. OF NEW YORK 30,150 ALLIANCE OF DEDICATED CANCER CTRS 53,200 OTHERS 4,468 TOTAL $ 406,495 false false 1327922000 26784000 -2684000 1352022000 1228619000 96214000 3089000 1327922000 1208893000 19598000 128000 1228619000 1123167000 59460000 26266000 1208893000 869056000 152114000 101997000 1123167000 0.42820 0.57180 false false 423133000 423133000 6058924000 2661581000 3397343000 111351000 99748000 11603000 2405480000 1817000 587885000 105746000 7146000 98600000 4518564000 PRIVATE EQUITY & VENTURE CAP. 2238842000 F 2238842000 0 POSTRETIREMENT OBLIGATIONS 101100000 INSURANCE RESERVES 315623000 DEFERRED COMPENSATION 80178000 ASSET RETIREMENT OBLIGATION 39209000 DEFERRED GIFT ANNUITY 11679000 OTHER LIABILITIES 1606000 ROYALTY INTEREST LIABILITY 122048000 THIRD PARTY SETTLEMENT 115781000 787224000 5664638216 -1613299000 49871216 -1563427784 7228066000 23881000 23881000 7251947000 6878496216 50370216 50370216 6828126000 23881000 23881000 6852007000 USE OF ENDOWMENT FUNDS PERMANENT ENDOWMENT FUNDS ARE HELD BY THE ORGANIZATION IN PERPETUITY. INCOME EARNED ON THE FUND BALANCE IS USED TO SUPPORT THE OPERATIONS OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATED ORGANIZATIONS. PART XI LINE 2D RENTAL EXPENSES OFFSETS REVENUE $48,914,000 SPECIAL EVENTS EXPENSES OFFSETS REVENUE 915,216 MMPC REV - SEPERATE 990 42,000 TOTAL $49,871,216 PART XII LINE 2D RENTAL EXPENSES OFFSETS REVENUE $48,914,000 SPECIAL EVENTS EXPENSES OFFSETS REVENUE 915,216 MMPC EXP - SEPERATE 990 541,000 TOTAL $50,370,216 FIN 48 - LIABILITY FOR UNCERTAIN TAX POSITIONS A FIN 48 FOOTNOTE DISCLOSURE, RELATING TO THE ACCOUNTING FOR INCOME TAXES, WAS NOT REQUIRED BECAUSE THERE WAS NO MATERIAL IMPACT ON THE INSTITUTION'S FINANCIAL STATEMENTS. true true true true true true true false false false false false false false false false false true NONDISCRIMINATORY POLICY THE SCHOOL'S NONDISCRIMINATORY POLICY IS PUBLICIZED ON ITS WEB SITE: https://www.sloankettering.edu/gerstner/admissions/requirements ALL APPLICANTS TO THE LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES ARE CONSIDERED ON THE BASIS OF MERIT. THE SCHOOL DOES NOT DISCRIMINATE ON THE BASIS OF GENDER, RACE, COLOR, CREED, RELIGION, AGE, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS, MARITAL STATUS, SEXUAL ORIENTATION, OR CITIZENSHIP STATUS IN ACCORDANCE WITH INSTITUTIONAL POLICY AND IN COMPLIANCE WITH THE REQUIREMENTS OF THE CIVIL RIGHTS ACT, THE EDUCATION AMENDMENTS, THE REHABILITATION ACT, THE AGE DISCRIMINATION ACT, AND THE AMERICANS WITH DISABILITIES ACT. EXCISE TAX ON NET INVESTMENT INCOME THE LOUIS V GERSTNER JR, GRADUATE SCHOOL OF BIOMEDICAL SCIENCES DOES NOT MEET THE CRITERIA OF SECTION 4968 AND, THEREFORE, IS NOT SUBJECT TO THE EXCISE TAX ON NET INVESTMENT INCOME. North America 0 1 Program Services PATIENT CARE SUPPORT 360896 Middle East and North Africa 0 2 Program Services PATIENT CARE SUPPORT 466383 Middle East and North Africa 0 2 Program Services ADMIN SUPPORT 310878 Europe (Including Iceland and Greenland) 0 6 Program Services ADMIN SUPPORT 855047 Europe (Including Iceland and Greenland) 0 4 Program Services RESEARCH SUPPORT 291879 East Asia and the Pacific 0 1 Program Services RESEARCH SUPPORT 59710 South Asia 0 1 Program Services ADMIN SUPPT CONFRENCES 8108 EUROPE 0 17 Program Services ADMIN SUPPT CONFRENCES 58336 Middle East and North Africa 0 1 Program Services ADMIN SUPPT CONFRENCES 4252 North America 0 2 Program Services ADMIN SUPPT CONFRENCES 1600 South Asia 0 3 Program Services PATIENT CARE CONFRENCE 28226 EUROPE 0 81 PROGRAM SERVICES PATIENT CARE CONFRENCE 592222 Middle East and North Africa 0 5 Program Services PATIENT CARE CONFRENCE 35767 North America 0 22 Program Services PATIENT CARE CONFRENCE 37175 East Asia and the Pacific 0 8 Program Services PATIENT CARE CONFRENCE 109440 Sub-Saharan Africa 0 16 Program Services PATIENT CARE CONFRENCE 90787 South America 0 6 Program Services PATIENT CARE CONFRENCE 14022 Central America and the Caribbean 0 2 Program Services PATIENT CARE CONFRENCE 1091 South Asia 0 1 PROGRAM SERVICES RESEARCH CONFRENCES 5129 EUROPE 0 57 PROGRAM SERVICES RESEARCH CONFRENCE 219158 Middle East and North Africa 0 9 PROGRAM SERVICES RESEARCH CONFRENCE 21861 North America 0 18 PROGRAM SERVICES RESEARCH CONFRENCE 18 East Asia and the Pacific 0 6 PROGRAM SERVICES RESEARCH CONFRENCE 48415 Sub-Saharan Africa 0 4 PROGRAM SERVICES RESEARCH CONFRENCE 5793 EUROPE 0 7 PROGRAM SERVICES EDUCATIONAL CONFRENCE 26646 Middle East and North Africa 0 2 PROGRAM SERVICES EDUCATIONAL CONFRENCE 2539 North America 0 3 PROGRAM SERVICES EDUCATIONAL CONFRENCE 2016 Central America and the Caribbean 0 0 INVESTMENTS 2229479449 Middle East and North Africa 0 0 INVESTMENTS 43044057 Europe (Including Iceland and Greenland) 0 0 INVESTMENTS 36536295 0 178 0 109 0 287 3324728 2309392467 2312717195 true false true true true false FOREIGN GRANTS AND INVESTMENTS MSKCC DOES NOT MAKE GRANTS OR USE GRANT MONEY OUTSIDE OF THE UNITED STATES VALUES SHOWN IN COLUMN F ARE THE MARKET VALUES FOR THE INVESTMENTS AT DECEMBER 31. All States Spring Ball 2443877 2366377 77500 97747 62400 129569 Winter Lunch 790255 753630 36625 57288 37999 4 1692451 1548596 143855 221457 127553 8000 173203 4926583 4668603 257980 221457 282588 70400 340771 915216 -657236 true true X true X 500. true X 500. true true true false true true 16789102 16789102 0.00250 343806877 108260224 235546653 0.03440 360595979 108260224 252335755 0.03690 15586011 312398 15273613 0.00220 237089883 55705708 181384175 0.02650 2164099 2164099 0.00030 755896061 396020798 359875263 0.05250 324601 324601 1011060655 452038904 559021751 0.08150 1371656634 560299128 811357506 0.11840 18733 18733 91210 91210 1667595 1667595 0.00020 91347 91347 1868885 1868885 0.00020 false 83522149 1779915 1559468018 2165604093 -606136075 X true true 1 1 MEMORIAL HOSP FOR CANCER & ALLIED DIS 1275 YORK AVENUE NEW YORK NY 10065 www.mskcc.org 7002020H X X X X Urgent Care Center SEE PART V OF SCH H MEMORIAL HOSP FOR CANCER & ALLIED DIS 1 false false true X X X X X X X X X 22 true true false true X www.mskcc.org/communityserviceplans X true 22 true www.mskcc.org/communityserviceplans false true X 500. 500. X X X X X X true true X X X X true X SEE SCH H, PART V, SECTION C X www.mskcc.org/financial-assistance X SEE SCH H, PART V, SECTION C X X X X X X X true X false X X X X true X false false PART V FACILITY INFORMATION LINE 3E WE PRIORITIZED THE IDENTIFIED CANCER-RELATED COMMUNITY HEALTH NEEDS BASED ON CERTAIN CRITERION AS OUTLINED IN MSK'S 2022-2024 CHNA AND LINKED THEM TO APPROPRIATE PROGRAMS AND ACTIVITIES AS DESCRIBED IN THE IMPLEMENTATION STRATEGIES POSTED TO OUR WEBSITE AT WWW.MSKCC.ORG/COMMUNITYSERVICEPLANS. LINE 5 TO UPDATE OUR UNDERSTANDING OF CURRENT CANCER-RELATED NEEDS WITHIN OUR CATCHMENT AREA, IN 2022 MSK INVITED COMMUNITY STAKEHOLDERS TO PARTICIPATE IN MSK'S COMMUNITY HEALTH NEEDS ASSESSMENT LEADERSHIP FORUM. INVITATIONS TO PARTNER IN OUR CHNA LEADERSHIP FORUM WERE SENT TO 225 COMMUNITY REPRESENTATIVES FROM WHICH 60 ORGANIZATIONS SERVING UNDERSERVED POPULATIONS PARTICIPATED. THESE ORGANIZATIONS ALSO HELPED DISSEMINATE THE GREATER NEW YORK HOSPITAL ASSOCIATION CHNA SURVEY TO THEIR AUDIENCES. PARTICIPANTS INCLUDED REPRESENTATIVES FROM COMMUNITY-BASED ORGANIZATIONS AND LOCAL HEALTH AGENCIES, LOCAL GOVERNMENT OFFICIALS, HEALTHCARE PROVIDERS, BUSINESSES, HEALTHCARE ADVOCATES, AND LABOR UNIONS. MSK'S VIRTUAL CHNA LEADERSHIP FORUM WAS HELD IN MAY 2022. PARTICIPANTS WERE ASSIGNED TO GROUPS RANGING IN SIZE BETWEEN 6-12 PEOPLE AND WERE ASKED TO SPEAK ON BEHALF OF THE DIVERSE LOCALIZED POPULATIONS THEIR ORGANIZATIONS AND AGENCIES SERVE INCLUDING HARLEM, QUEENS, BROOKLYN, NEW JERSEY, LONG ISLAND, AND WESTCHESTER. MSK'S CHNA COMMITTEE DEVELOPED A DISCUSSION GUIDE, WHICH SUPPORTED DEFINING CANCER-RELATED HEALTH PRIORITIES AND CONCERNS FACING AREA RESIDENTS (ESPECIALLY FOR DIVERSE AND MEDICALLY UNDERSERVED POPULATIONS) AND EXPLORING OPPORTUNITIES FOR MSK TO PARTNER WITH COMMUNITY-BASED ORGANIZATIONS TO ADDRESS HEALTH DISPARITIES. LEADING HEALTH NEEDS WERE IDENTIFIED BY GROUP CONSENSUS AND CATEGORIZED INTO FIVE BROAD AREAS FOR IMPROVING CANCER OUTCOMES: SOCIAL DETERMINANTS OF HEALTH, ACCESS TO CLINICAL SERVICES, LANGUAGE AND CULTURAL SENSITIVITY, SOCIAL SUPPORT AND COMMUNITY PARTNERSHIPS. AFTER THE FORUM, THE FINDINGS WERE SHARED WITH OUR CHNA PARTNERS FOR CONFIRMATION AND ADDITIONAL FEEDBACK. COMMUNITY ORGANIZATIONS THAT PROVIDED INPUT FOR MSK'S CHNA INCLUDE: A BETTER COLLEGE POINT CIVIC ASSOCIATION ADELPHI NY STATEWIDE BREAST CANCER HOTLINE AMERICAN CANCER SOCIETY ARAB AMERICAN ASSOCIATION OF NY ARAB AMERICAN FAMILY SUPPORT CENTER BREAST CANCER ALLIANCE BRONX HEALTH & HOUSING CONSORTIUM BRONX HEALTH REACH BROOKLYN COLLEGE CANCER CENTER BROTHER TO BROTHER CALLEN LORDE CANCER AND CAREERS CANCER CARE CANCER SUPPORT TEAM COALICIN MEXICANA COUNCILWOMAN MERCEDES NARCISSE OFFICE, 46TH DISTRICT CSP OF NASSAU COUNTY DILIGENTLY SERVING IMMIGRANTS INC. GILDA'S - RED DOOR COMMUNITY GILDA'S CLUB OF WESTCHESTER HEADSTRONG FOUNDATION HOPE COMMUNITIES INC. LATINA SHARE LATINO COMMISSION ON AIDS - NYC REGION LEUKEMIA & LYMPHOMA SOCIETY LONG ISLAND NETS MAKE THE ROAD NY MEXICAN CONSULATE / VENTANILLA DE SALUD MIDDLESEX COUNTY OFFICE OF HEALTH SERVICES MOLLOY COLLEGE MONMOUTH COUNTY REGIONAL HEALTH COMMISSION NO. 1 NASSAU COUNTY DEPARTMENT OF HEALTH NASSAU LIBRARY SYSTEM NATIONAL ASSOCIATION OF NIGERIAN NURSES IN NORTH AMERICA NJCEED NOSTRAND GARDENS CIVIC ASSOCIATION NEW YORK CITY DISTRICT COUNCIL OF CARPENTERS OCEAN MONMOUTH HEALTH ALLIANCE OPEN DOOR FAMILY MEDICAL CENTERS RISEBOROUGH COMMUNITY PARTNERSHIPS RYE YMCA SISTERS UNITED IN HEALTH SOMERSET MORRIS CHRONIC DISEASE COALITION SOUL RYEDERS SOUTH ASIAN COUNCIL FOR SOCIAL SERVICES SUNNYSIDE COMMUNITY SERVICES SUPPORT CONNECTION SUSAN G. KOMEN BREAST CANCER ORGANIZATION THE ABYSSINIAN BAPTIST CHURCH THE BUSINESS COUNCIL OF WESTCHESTER THE COLETTE COYNE MELANOMA AWARENESS CAMPAIGN THE ISAACS CENTER AND GODDARD RIVERSIDE COMMUNITY CENTER UNION COUNTY OFFICE OF HEALTH MANAGEMENT UNION FOUTA UNIONDALE LIBRARY VISITING NURSES SERVICE OF NEW YORK - VNSNY CHOICE VNACJ COMMUNITY HEALTH CENTER WESTCHESTER JEWISH COMMUNITY SERVICES WYCKOFF HEALTH MEDICAL CENTER POSITIVE HEALTH MANAGEMENT LINE 6A MSK PARTICIPATED IN THE GREATER NEW YORK HOSPITAL ASSOCIATION (GNYHA) CHNA SURVEY COLLABORATIVE, COMPRISING OF 14 HOSPITALS AND HEALTH SYSTEMS. THE COLLABORATIVE WAS CONVENED TO SUPPORT AND STREAMLINE HOSPITAL EFFORTS IN IDENTIFYING LEADING COMMUNITY HEALTH NEEDS AND HELPING MEET THE REQUIREMENTS OF THE FEDERAL CHNA AND THE NEW YORK STATE COMMUNITY SERVICE PLAN. MEMBER HOSPITALS AGREED TO DISSEMINATE A SURVEY THAT WAS THEN ANALYZED BY GNYHA. THE FOLLOWING HOSPITALS AND HEALTH SYSTEMS PARTICIPATED IN THE GNYHA CHNA SURVEY COLLABORATIVE: MAIMONIDES MEDICAL CENTER AND NEW YORK COMMUNITY HOSPITAL MEDISYS HEALTH NETWORK MEMORIAL SLOAN KETTERING CANCER CENTER MONTEFIORE HEALTH SYSTEM NEWYORK-PRESBYTERIAN HOSPITAL NIAGARA FALLS MEMORIAL MEDICAL CENTER NORTHWELL HEALTH NUVANCE HEALTH ONE BROOKLYN HEALTH SYSTEM SBH HEALTH SYSTEM/ST. BARNABAS HOSPITAL ST. JOHN'S RIVERSIDE HOSPITAL THE ROCKEFELLER UNIVERSITY WMC HEALTH NETWORK LINE 7D SUMMARY FINDINGS OF MSK'S COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) WERE SENT TO COMMUNITY-BASED ORGANIZATIONS WITH WHOM WE WORKED AND INVITED THEIR FEEDBACK. WE ALSO INCORPORATED THE CHNA INTO OUR 2022-2024 NEW YORK STATE COMMUNITY SERVICE PLAN (CSP) TO ADDRESS THE IDENTIFIED HEALTH NEEDS. THE FINAL REPORT IS BEING SHARED VIA EMAIL WITH AREA OFFICIALS AND HEALTH AGENCIES, CIVIC LEADERS, AND COMMUNITY ORGANIZATIONS. IT IS ALSO PUBLISHED ON MSK'S WEBSITE FOR PUBLIC INFORMATION AND INPUT AT MSKCC.ORG/COMMUNITYSERVICEPLANS. MSK IS PLANNING A FOLLOW UP FORUM WITH CHNA PARTICIPANTS IN 2023 TO SHARE OUR IMPLEMENTATION PLAN AND INVITE FEEDBACK. MSK WILL MAKE ANNUAL UPDATES TO ITS COMMUNITY SERVICE PLAN WHENEVER REQUIRED BY THE NEW YORK DEPARTMENT OF HEALTH. LINE 11 MSK HAS A LONG-STANDING COMMITMENT TO ADDRESS MANY OF THE CANCER-RELATED NEEDS IDENTIFIED THROUGH ITS RECENT CHNA. THE CHNA SURVEY DEVELOPED BY GNYHA AND DISSEMINATED TO COMMUNITY MEMBERS BY 14 HOSPITALS AND HEALTH SYSTEMS, INCLUDING MSK, CONFIRMED CANCER IS A LEADING CAUSE OF DEATH AND AN IMPORTANT CONCERN OF THE COMMUNITY. MSK'S COMMUNITY BENEFIT PROGRAMS WILL CONTINUE TO INCLUDE AN ARRAY OF CANCER-FOCUSED ACTIVITIES AROUND RESEARCH, EDUCATION, PATIENT FINANCIAL ASSISTANCE, AND PATIENT SCREENING AND CARE. IN ADDITION, MSK WILL CONTINUE TO SUPPORT THE TOBACCO PREVENTION AND CHRONIC DISEASE PREVENTIVE CARE AND MANAGEMENT FOCUS AREAS OF THE NEW YORK STATE PREVENTION AGENDA. MSK IS CURRENTLY ADDRESSING MANY OTHER CANCER-FOCUSED TOPICS IDENTIFIED THROUGH THE CHNA, INCLUDING ACCESS TO CLINICAL SERVICES, SOCIAL DETERMINANTS OF HEALTH, AND LANGUAGE AND CULTURAL SENSITIVITY. FOR EXAMPLE, MSK'S RALPH LAUREN CENTER PROVIDES FREE AND DISCOUNTED CANCER CARE, PREVENTION, AND SCREENING, AS WELL AS HEALTH-RELATED AND NUTRITIONAL EDUCATION AT NO COST TO THE COMMUNITY. IN 2023, MEMORIAL MEDICAL CARE, PC, A PRACTICE OF MSK PHYSICIANS, OPENED IN THE FLATBUSH NEIGHBORHOOD OF BROOKLYN. THIS NEW FACILITY PROVIDES GREATER ACCESS TO CARE FOR THE FLATBUSH COMMUNITY, WHERE 22 PERCENT OF RESIDENTS LIVE IN POVERTY, AND CANCER IS THE LEADING CAUSE OF PREMATURE DEATH. THE SITE CONNECTS PATIENTS TO ADVANCED IMAGING, STATE-OF-THE-ART THERAPIES, AND CUTTING-EDGE CLINICAL TRIALS AT MSK'S OTHER FACILITIES. PROGRAMS THROUGH MSK'S IMMIGRANT HEALTH AND CANCER DISPARITIES SERVICE (IHCD) ADDRESS PREVENTION/SCREENING, NUTRITION EDUCATION, AND HEALTHCARE REFERRALS FOR IMMIGRANTS. THESE PROGRAMS INCLUDE THE ARAB HEALTH INITIATIVE, VENTANILLA DE SALUD (HEALTH WINDOW WITH MEXICAN CONSULATE), MOBILE HEALTH UNIT, AND THE TAXI NETWORK, AMONG OTHERS. IHCD ALSO RUNS THE FOOD TO OVERCOME DISPARITIES PROGRAM (F.O.O.D.), WHICH TACKLES FOOD INSECURITY AMONG UNDERSERVED CANCER PATIENTS BY PROVIDING NUTRITION EDUCATION AND FREE NUTRITIOUS FOODS THROUGH FOOD PANTRIES AT 15 CANCER TREATMENT SITES ACROSS NEW YORK CITY AND LONG ISLAND. F.O.O.D. PARTNERS WITH COMMUNITY-BASED ORGANIZATIONS, HOSPITALS AND OTHER AGENCIES TO CONDUCT RESEARCH ON THE IMPACT OF THE PROGRAM TO DECREASE FOOD INSECURITY AND INCREASE CANCER TREATMENT ADHERENCE AND PATIENT OUTCOMES. MSK'S TOBACCO TREATMENT PROGRAM (TTP) WORKS TO REDUCE TOBACCO-RELATED CANCER BURDENS AND ADDRESSES DISPARITIES THROUGH EVIDENCE-BASED CLINICAL CARE, EDUCATION, TRAINING, COMMUNITY OUTREACH, AND RIGOROUS RESEARCH. TO ADDRESS LANGUAGE ASSISTANCE FOR LIMITED ENGLISH PROFICIENCY PATIENTS, MSK ENSURES ALL PATIENTS AND FAMILIES ARE ABLE TO CONNECT TO HIGH-QUALITY CANCER CARE THROUGH MEDICAL INTERPRETING AND TRANSLATION SERVICES. MSK ALSO PRODUCES ONLINE AND PRINT RESOURCES IN MULTIPLE LANGUAGES, INCLUDING ALBANIAN, ARABIC, BENGALI, CHINESE, FRENCH, GERMAN, GREEK, GUJARATI, HEBREW, HINDI, ITALIAN, JAPANESE, KOREAN, POLISH, PORTUGUESE, PUNJABI, RUSSIAN, SPANISH, UKRAINIAN, URDU, VIETNAMESE, AND YIDDISH. ALL MATERIALS PRODUCED ARE AVAILABLE TO THE PUBLIC IN A VIRTUAL PATIENT EDUCATION LIBRARY AT MSKCC.ORG/PE. THE LIBRARY HOSTS OVER 5,000 EDUCATIONAL RESOURCES AND HAD OVER 88 MILLION VIEWS SINCE 2020. IN ADDITION, FOR MORE THAN 20 YEARS, MSK'S MEDICAL INTERPRETING TRAINING AND EDUCATION PROGRAM HAS ADDRESSED THE LANGUAGE BARRIERS IN HEALTHCARE BY TRAINING BILINGUAL INDIVI 5 MSK MONMOUTH 480 RED HILL ROAD MIDDLE TOWN NJ 07748 EXTENSION CLINIC MSK BERGEN 225 SUMMIT AVENUE MONTVALE NJ 07901 EXTENSION CLINIC MSK BASKING RIDGE 136 MOUNTAIN VIEW BLVD BASKING RIDGE NJ 07920 EXTENSION CLINIC MSK CLINICAL GENETICS SERVICES 222 EAST 70TH STREET NEW YORK NY 10021 EXTENSION CLINIC BENDHEIM CENTER FOR INTEGRATED MEDICINE 205 E64TH STREET NEW YORK NY 10065 EXTENSION CLINIC SCHEDULE H, PART VI PART 1, LINE 3A A PATIENT WITH INCOME LESS THAN OR EQUAL TO 500% OF THE FEDERAL POVERTY GUIDELINES IS ELIGIBLE FOR THE INSTITUTION'S FINANCIAL ASSISTANCE PROGRAM (FAP). THE INSTITUTION MAY REDUCE THE FEES INCURRED BY THE PATIENT OR ACCEPT AS FULL PAYMENT AMOUNTS PAID BY THE INSURANCE CARRIER ON THE PATIENT'S BEHALF. IN ADDITION, A PATIENT MAY ALSO QUALIFY FOR ASSISTANCE EVEN IF HIS/HER INCOME IS GREATER THAN THE THRESHOLD LIMIT. THE INSTITUTION ADJUSTS PATIENTS' INCOME FOR ROUTINE MONTHLY EXPENSES, INCLUDING TAXES, TO DETERMINE "DISPOSABLE INCOME". MSK ALSO DEDUCTS A SPECIFIC AMOUNT (DEBT BURDEN) AS A MONTHLY CLOTHES AND FOOD ALLOWANCE BASED ON A PATIENT'S FAMILY SIZE IN EVALUATING THE TYPE AND AMOUNT OF ASSISTANCE NEEDED. THE TABLE BELOW ILLUSTRATES THE INCOME GUIDELINE USED IN EVALUATING THE PATIENT'S FINANCIAL STATUS. FAMILY SIZE ALLOWED INCOME RESOURCE LEVELS 1 $ 67,950 $ 42,000 2 $ 91,550 $ 61,500 3 $115,150 $ 62,535 4 $138,750 $ 70,688 5 $162,350 $ 78,848 6 $185,950 $ 87,000 PART 1, LINE 3C THE MAXIMUM AMOUNT CHARGED TO PATIENTS DEEMED ELIGIBLE UNDER THE FAP FOR "EMERGENCY OR OTHER MEDICALLY NECESSARY CARE" IS THE AMOUNT THE INSTITUTION INITIALLY CONCLUDED A PATIENT CAN AFFORD TO PAY WHEN FINALIZING THE FAP APPLICATION. THIS AMOUNT IS DERIVED BY CALCULATING A PATIENT'S HOUSEHOLD "NET MONTHLY INCOMEDEDUCTING THE TOTAL AMOUNT OF ROUTINE MONTHLY BILLS. THE AMOUNT REMAINING IS WHAT WE CONSIDER THE PATIENT CAN PAY EACH MONTH. IF THE PATIENT'S HOUSEHOLD MONTHLY ROUTINE BILLS ARE MORE THAN OR EQUAL TO "NET MONTHLY INCOME", THE INSTITUTION ACCEPTS WHATEVER THE PATIENT'S INSURANCE PAYS AS PAYMENT IN FULL, (THE PATIENT WOULD NOT HAVE TO PAY ANYTHING OUT-OF-POCKET); UNLESS THE PATIENT HAS ASSETS SUCH AS A SECOND HOME, STOCKS, CERTIFICATE OF DEPOSITS, LARGE SAVINGS OR ANY OTHER ASSETS EXCLUDING RETIREMENT AND EDUCATION ACCOUNTS. PATIENTS WITH LARGE AMOUNTS OF ASSETS WHOSE ROUTINE MONTHLY BILLS ARE GREATER THAN THEIR "NET MONTHLY INCOME" MAY BE ELIGIBLE FOR REDUCED TIME AND PAYMENT ARRANGEMENT AND WOULD MAKE MONTHLY PAYMENTS (12 TO 18 MONTHS) TO PAY OFF THE AMOUNT THE INSTITUTION DETERMINED THEY CAN AFFORD TO PAY. ONCE THE FAP APPLICATION IS FINALIZED AND A PATIENT IS DEEMED ELIGIBLE TO PAY NOTHING OR A REDUCED TIME PAYMENT, THIS AGREEMENT IS EFFECTIVE FOR ONE YEAR AND INCLUDES THE PATIENT'S OUTSTANDING BALANCES. ALL PATIENTS ARE ADVISED OF MSK'S FAP, BUT AGAIN THE DETERMINATION IS ONLY DOCUMENTED IF THE PATIENT APPLIES FOR THE ASSISTANCE. PART I, LINE 7G MEMORIAL SLOAN KETTERING HAS CONSISTENTLY SET THE STANDARD OF CARE FOR PEOPLE WITH CANCER BY EMPHASIZING EARLY DETECTION, PRECISE DIAGNOSIS, AND INDIVIDUALLY TAILORED TREATMENT. THE HOSPITAL SUBSIDIZES CANCER SCREENING, TREATMENT, AND SUPPORT SERVICES TO FULFILL ITS MISSION AND TO HELP REDUCE CANCER HEALTH DISPARITIES AMONG MINORITY AND MEDICALLY UNDERSERVED POPULATIONS. THE RALPH LAUREN CENTER AT MEMORIAL SLOAN KETTERING CANCER CENTER WAS ESTABLISHED IN 2003 WITH GENEROUS FUNDING FROM THE RALPH LAUREN CORPORATE FOUNDATION AND THE LAUREN FAMILY TO ADDRESS SIGNIFICANT HEALTH DISPARITIES FOUND IN LOW-INCOME AND HISTORICALLY UNDERSERVED COMMUNITIES IN NEW YORK CITY. LOCATED IN HARLEM AND ASSISTING PEOPLE FROM ALL FIVE BOROUGHS, THE RALPH LAUREN CENTER (RLC) IS A MODEL FOR BROADENING ACCESS TO HIGH-STANDARD CANCER PREVENTION, DIAGNOSTICS, AND TREATMENT SERVICES. IN 2019, THE RLC WAS INCORPORATED WITHIN MSK, CREATING IMPORTANT OPPORTUNITIES TO EXPAND AND INCREASE SUSTAINABLE BENEFITS TO UNDERSERVED NEW YORKERS AFFECTED BY CANCER. MSK ALSO MERGED ITS BREAST EXAMINATION CENTER OF HARLEM INTO THE RLC THAT YEAR, STREAMLINING EFFORTS IN ONE CONVENIENT LOCATION. MSK RALPH LAUREN CENTER PROVIDES CANCER PREVENTION, SCREENING, DIAGNOSIS, TREATMENT, AND SOCIAL SERVICES, AS WELL AS FINANCIAL COUNSELING AND A FOOD PANTRY SUPPLEMENTED WITH NUTRITIONAL COUNSELING. RLC'S SCOPE OF SERVICES INCLUDE BREAST CANCER EVALUATION, DIAGNOSTIC AND TREATMENT SERVICES, INCLUDING CHEMOTHERAPY, FOR MOST CANCERS AND BLOOD DISEASES, AND SCREENING SERVICES FOR BREAST, CERVICAL, COLON, PROSTATE AND LUNG CANCER AND SMOKING CESSATION PROGRAM. RLC IS STAFFED BY MEDICAL ONCOLOGISTS, A BREAST SURGEON, APP'S, REGISTERED NURSES, PATIENT CARE TECHNICIANS, A DIETICIAN/NUTRITIONIST, RADIOLOGY TECHNOLOGISTS, AND LAB TECHNICIANS. REFERRALS TO CLINICIANS, PROGRAMS, AND FACILITIES WITHIN MEMORIAL HOSPITAL ARE COORDINATED FOR PATIENTS REQUIRING SUCH SERVICES. TO-DATE RLC HAS MANAGED MORE THAN 186,826 PATIENT VISITS SINCE ITS FOUNDING. APPROXIMATELY 22,326 VISITS WERE MADE BETWEEN APRIL 1, 2019 AND DECEMBER 31, 2022 WHEN RLC TRANSITIONED TO MSK. MORE THAN 2,324 FINANCIAL ASSESSMENTS WERE ALSO RECORDED, DURING THE PERIOD APRIL 1, 2019 AND DECEMBER 31, 2022. MEMORIAL SLOAN KETTERING'S PSYCHIATRY & BEHAVIORAL SERVICES DEPARTMENT IS COMMITTED TO THE URGENT AS WELL AS ROUTINE CARE OF PATIENTS WITH CANCER. OUR PSYCHIATRISTS AND PSYCHOLOGISTS HAVE EXPERTISE IN ASSISTING PATIENTS WITH THE SPECTRUM OF PSYCHIATRIC AND BEHAVIORAL ISSUES THAT CAN ARISE DURING DIAGNOSIS AND TREATMENT. THE DEPARTMENT ALSO WORKS TO DEEPEN ITS UNDERSTANDING AND EXPAND TREATMENT OPTIONS FOR ONCOLOGY PATIENTS AROUND THE GLOBE THROUGH CLINICAL TRIALS, RESEARCH, AND OTHER MEANS. TO ACCOMPLISH THESE GOALS, THE DIVISION OFFERS INPATIENT AND OUTPATIENT PSYCHOLOGICAL AND SOCIAL SUPPORT SERVICES TO PATIENTS, THEIR FAMILIES, AND CAREGIVERS. FUNDING FOR THE MEDICAID OUTPATIENT VISITS AND INPATIENT ENCOUNTERS ARE SUBSIDIZED BY MSK, AS ARE UNREIMBURSED TIME AND EFFORT BY NURSES TO STAFF A SMOKING CESSATION CLINIC. PHILANTHROPIC FUNDS ARE USED TO SUPPORT A SIGNIFICANT NUMBER OF THE DEPARTMENT'S OVERALL CLINICAL AND TRAINING ACTIVITIES. SERVICES PROVIDED INCLUDE CONSULTATIONS AND EVALUATION, PSYCHOTHERAPY, MEDICATION MANAGEMENT AND PHARMACOTHERAPY, SUPPORTIVE COUNSELING, SMOKING CESSATION, HYPNOTHERAPY, VARIOUS DIAGNOSTIC TESTS, AND OTHERS. DURING 2022, THE DEPARTMENT EXPERIENCED 27,216 INPATIENT AND OUTPATIENT ENCOUNTERS WITH 1,996 PATIENTS TREATED THROUGH THE SMOKING CESSATION PROGRAM. APPROXIMATELY $5.00M WAS EXPENDED BY THE DEPARTMENT TO SUPPORT ITS COMMUNITY BENEFIT-RELATED PROGRAMS, OF WHICH $1.80M, OR 36%, WERE INCURRED FOR SUBSIDIZED CLINICAL CARE. AT MSK WE BELIEVE IN CARING FOR THE WHOLE PERSON, NOT JUST THE DISEASE OR SYMPTOM. INTEGRATIVE MEDICINE WEAVES NATURAL TREATMENTS SUCH AS ACUPUNCTURE, MASSAGE, AND YOGA INTO OUR OVERALL CARE PLAN. ALL OF OUR HOLISTIC HEALTH SERVICES AND PROGRAMS ARE BASED ON THE LATEST SCIENTIFIC EVIDENCE. THE INTEGRATIVE MEDICINE SERVICE PROVIDES FREE CLINICAL CARE FOR INPATIENTS. DURING 2022, WE SERVICED 6,656 INPATIENT VISITS. THESE CLINICAL SERVICES INCLUDED MUSIC THERAPY, TOUCH THERAPY, ACUPUNCTURE, YOGA AND YOGIC BREATHING, MEDITATION AND GUIDED IMAGERY, KARATE AND DANCE THERAPY. WE ALSO PROVIDED EXTENSIVE EDUCATION FOR PATIENTS AND CAREGIVERS DURING BEDSIDE AND GROUP VISITS. THESE SERVICES ARE ALSO AVAILABLE FREE OF CHARGE TO PATIENTS SEEN ON THE OUTPATIENT PEDIATRIC FLOOR. DURING 2022, 995 OUTPATIENT PEDIATRIC VISITS WERE COMPLETED. IN ADDITION, WE OFFER OUTPATIENT ACUPUNCTURE CONSULTATIONS TO ANYONE IN THE COMMUNITY AT NO COST TO THEM. THESE CONSULTATIONS ADVISED CLIENTS ON HOW ACUPUNCTURE BENEFIT THEIR CONDITION BASED ON THEIR SPECIFIC THERAPEUTIC NEEDS. THERE WERE 87 ACUPUNCTURE CONSULTATIONS PROVIDED IN 2022. THE DEPARTMENT INCURRED $1.11M IN PERSONNEL COST TO DELIVER COMMUNITY BENEFIT-RELATED PROGRAMS. $.35M OR 30% WERE SPENT ON SUBSIDIZED CLINICAL CARE. PART I, LINE 7, COL (F) THE BAD DEBT EXPENSE WAS NOT INCLUDED ON LINE 25 IN ACCORDANCE WITH GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (GAAP). PART I, LINE 7 FINANCIAL ASSISTANCE REPRESENTS THE COST OF SERVICES PROVIDED TO PATIENTS WHO CANNOT AFFORD HEALTH CARE SERVICES DUE TO INADEQUATE RESOURCES AND/OR ARE UNINSURED OR UNDERINSURED. A PATIENT IS CLASSIFIED AS A FINANCIAL ASSISTANCE PATIENT IN ACCORDANCE WITH THE INSTITUTION'S ESTABLISHED POLICIES AND WHERE INSUFFICIENT PAYMENT FOR SUCH SERVICES IS ANTICIPATED. THE INSTITUTION CONSIDERS PATIENTS FOR FINANCIAL ASSISTANCE IF HOUSEHOLD INCOME IS LESS THAN 500% OF THE FEDERAL POVERTY GUIDELINES, AND AS DESCRIBED IN OTHER SECTIONS OF THIS DOCUMENT. SERVICES PROVIDED AS FINANCIAL ASSISTANCE ARE NOT REPORTED AS REVENUE. THE COSTS REPORTED IN THE TABLE ON LINE 7, WERE BASED ON VARIOUS SOURCES. FINANCIAL ASSISTANCE AND THE UNREIMBURSED MEDICAID COST WERE BASED ON A COST-TO-CHARGE RATIO CALCULATION. THE TOTAL CHARGES ASSOCIATED WITH THESE PROGRAMS ARE MULTIPLIED BY A RATIO OF HISTORICAL EXPENSES TO CHARGES AS DERIVED FROM THE HOSPITAL'S NEW YORK STATE INSTITUTIONAL COST REPORT. THE COSTS ASSOCIATED WITH A PORTION OF THE HEALTH PROFESSIONAL EDUCATION COMMUNITY BENEFIT ARE OBTAINED FROM THE STEP-DOWN OF COSTS PREPARED AS PART OF THE NEW YORK STATE INSTITUTIONAL COST REPORT. TO ARRIVE AT THE AMOUNTS REPORTED IN THE TABLE ON LINE 7, ADDITIONAL STEPS AS OUTLINED BELOW WERE TAKEN. UNPAID COST OF GOVERNMENT-SPONSORED HEALTH CARE REPRESENTS THE ESTIMATED DIFFERENCE BETWEEN THE PAYMENTS MADE UNDER THE MEDICARE AND MEDICAID PROGRAMS AND THE INSTITUTION'S COST OF PROVIDING THESE SERVICES AS CALCULATED ABOVE. THE INSTITUTION SUBTRACTS ALL REVENUES RECEIVED FROM THE MEDICARE AND MEDICAID PROGRAMS TO DETERMINE THE COMMUNITY BENEFIT PROVIDED. RESEARCH COMMUNITY BENEFIT COSTS REPRESENT ALL COSTS FOR BASIC TRANSLATIONAL AND CLINICAL RESEARCH, SUPPORTED BY INSTITUTIONAL FUNDS, GOVERNMENTAL, AND OTHER NON-PROFIT ORGANIZATIONS. THE INSTITUTION IS A PREEMINENT PROVIDER OF HEALTH TRAINING TO HEALTH PROFESSIONALS WHO DESIRE TRAINING IN THE SKILLS NECESSARY TO TREAT CANCER PATIENTS. THE INSTITUTION TRAINS PHYSICIANS, SCIENTISTS, MEDICAL STUDENTS, RADIOLOGY STUDENTS, NURSING STUDENTS, SOCIAL WORK STUDENTS AND INDIVIDUALS LOOKING TO CREATE A CAREER IN THE FIELD OF CANCER BIOLOGY. THE AMOUNTS REPORTED AS HEALTH TRAINING REPRESENT INSTITUTIONAL FUNDS, AS WELL AS COSTS IN EXCESS OF AMOUNTS REIMBURSED BY THIRD-PARTY PAYERS SUCH AS TRAINING GRANT REVENUES AND DIRECT MEDICAL EDUCATION PAYMENTS FROM THE MEDICARE PROGRAM. AS INDICATED EARLIER, MSK'S PSYCHIATRY & BEHAVIORAL SERVICES DEPARTMENT OFFERS INPATIENT AND OUTPATIENT PSYCHOLOGICAL SERVICES AND OTHER QUALIFYING SUBSIDIZED COMMUNITY BENEFIT PROGRAMS TO PATIENTS. SUBSIDIZED CANCER SCREENINGS ARE ALSO OFFERED THROUGH OTHER COMMUNITY PROGRAMS PROVIDED BY THE INSTITUTION. THE COST ASSOCIATED WITH THESE PATIENTS' CARE ARE REPORTED IN THE TABLE ON LINE 7, BASED ON PATIENT CARE COST TO CHARGE RATIO, WHERE APPLICABLE. ALL SALARY EXPENSES RELATED TO OTHER SUBSIDIZED PATIENT CARE BY ATTENDING PHYSICIANS, CLINICAL AND RESEARCH FELLOWS AND NURSE PRACTITIONERS ARE ALSO REPORTED IN THE TABLE ON LINE 7G. PART II MSK ENGAGES IN AND SUPPORTS COALITION-BUILDING ACTIVITIES THAT PROMOTE THE HEALTH OF THE COMMUNITIES THE INSTITUTION SERVES. STAFF MEMBERS ARE ENCOURAGED TO SHARE THEIR CLINICAL EXPERTISE AND EXPERIENCE WITH PARTNERING HEALTHCARE FACILITIES AND COMMUNITY ORGANIZATIONS. STAFF MEMBERS SERVE AND PARTICIPATE IN NUMEROUS COMMUNITY GROUPS INCLUDING THE AMERICAN CANCER SOCIETY, THE GREATER NEW YORK HOSPITAL ASSOCIATION, AND MANY HEALTH IMPROVEMENT ADVOCACY GROUPS FOR VARIOUS TYPES OF CANCER. ALTHOUGH THE SIGNIFICANT COST OF STAFF TIME DEVOTED TO THESE ACTIVITIES IS NOT QUANTIFIED BY THE CENTER, THE INSTITUTION CONSIDERS THESE EFFORTS TO COLLABORATE AND BUILD COMMUNITY RESOURCES TO BE OF SIZEABLE COMMUNITY BENEFIT. PART III, LINE 2 THE AMOUNT ON LINE 2 OF PART III IS THE ACTUAL 2022 BAD DEBT WRITE-OFF WHICH IS DERIVED BY TAKING THE GROSS CHARGES ASSOCIATED WITH THE PROVISIONS FOR BAD DEBTS AND MULTIPLYING BY A RATIO OF HISTORICAL EXPENSES TO CHARGES AS DERIVED FROM THE HOSPITAL'S NEW YORK STATE INSTITUTIONAL COST REPORT. A SEPARATE RATIO IS CALCULATED FOR EACH TYPE OF PATIENT CARE ACTIVITY: INPATIENT, OUTPATIENT, AND PHYSICIAN. PART III, LINE 3 PATIENTS CAN PURSUE FINANCIAL ASSISTANCE THROUGH MSK'S FINANCIAL ASSISTANCE PROGRAM. IF A PATIENT IS FOUND TO HAVE THE APPROPRIATE RESOURCES TO PAY FOR HEALTH SERVICES AND DOES NOT OR CHOOSES NOT TO PARTICIPATE IN AVAILABLE HEALTH BENEFIT PROGRAMS, THE INSTITUTION WILL BEGIN COLLECTION PROCEEDINGS IN ACCORDANCE WITH THE INSTITUTION'S POLICY. ONCE DEEMED UNCOLLECTABLE, THE CHARGES ARE CLASSIFIED AS BAD DEBTS AND ARE CHARGED OFF AS SUCH. THE AMOUNT ON LINE 3, OF PART III, REFLECTS THE COST OF THESE ACCOUNTS AS CALCULATED BASED ON THE COST-TO-CHARGE RATIO METHODOLOGY DESCRIBED EARLIER. IN DETERMINING THE AMOUNT THAT REASONABLY COULD BE ATTRIBUTABLE TO PATIENTS WHO LIKELY WOULD QUALIFY FOR FINANCIAL ASSISTANCE UNDER THE INSTITUTION'S POLICY, THE INSTITUTION REVIEWED THE CASES THAT WERE CLOSED WITH AN "INCOMPLETE" STATUS IN THE FINANCIAL ASSISTANCE PROGRAM DURING 2018 THROUGH 2022. THE INSTITUTION THEN COMPARED THESE CASES AGAINST THE BAD DEBT WRITE-OFFS FROM 2022. PART III, LINE 4 THE INSTITUTION FOLLOWS GENERALLY ACCEPTED ACCOUNTING PRINCIPLES IN REPORTING ON BAD DEBT EXPENSES. THEREFORE, A DETAILED DESCRIPTION OF THE BAD DEBT POLICY IS NOT REQUIRED IN THE FOOTNOTES TO THE AUDITED FINANCIAL STATEMENTS. PART III, LINE 8 THE MEDICARE LOSS REFLECTS LOSSES FROM BOTH HOSPITAL AND PHYSICIANS' ACTIVITY. PHYSICIAN REVENUE IS SHOWN AS OTHER REVENUE ON THE MEDICARE COST REPORT. COSTS DISALLOWED BY THE MEDICARE PROGRAM, BUT WHICH ARE INCURRED IN PROVIDING CARE TO MEDICARE BENEFICIARIES HAVE BEEN INCLUDED. PART III, LINE 9B THE INSTITUTION DOES NOT PURSUE COLLECTIONS FROM PATIENTS APPLYING FOR FINANCIAL ASSISTANCE. IF, HOWEVER, COLLECTIONS WERE INITIATED, THE EFFORT IS IMMEDIATELY SUSPENDED WHEN THE PATIENT APPLIES FOR FINANCIAL ASSISTANCE. IF THE PATIENT QUALIFIES FOR THE FAP WITH ZERO FEE PAYMENT, THE INSTITUTION ACCEPTS AS FULL SETTLEMENT ANY AMOUNT PAID BY THE INSURANCE CARRIER ON THE PATIENT'S BEHALF. ADDITIONALLY, IF A PATIENT QUALIFIES FOR A TIME PAYMENT PLAN (TPP), ALL OTHER CHARGES APART FROM THE AGREED TPP AMOUNT IS WRITTEN OFF AS FINANCIAL ASSISTANCE. FOR EXAMPLE, IF THE AGREEMENT CALLS FOR THE PATIENT TO MAKE AN ANNUAL PAYMENT OF $2,400 ($200 MONTHLY), THEN ALL OTHER CHARGES ACCRUING TO THE PATIENT ARE CANCELED AND WRITTEN OFF AS FINANCIAL ASSISTANCE. ANNUALLY, THE PATIENT'S CASE IS RE-EVALUATED AND ADJUSTMENTS MADE BASED ON CHANGING CIRCUMSTANCES. PART VI, LINE 2 THE CHNA IS THE MEANS BY WHICH THE INSTITUTION ASSESSES THE HEALTH NEEDS OF THE COMMUNITY. SEE PART V, SECTION B. PART VI, LINE 3 SINCE 1987, MSK HAS HAD A FINANCIAL ASSISTANCE PROGRAM IN PLACE TO ASSIST UNDERINSURED AND UNINSURED PATIENTS WHO ARE EXPERIENCING DIFFICULTIES MEETING THEIR FINANCIAL RESPONSIBILITIES TO MEMORIAL HOSPITAL AND ITS PHYSICIANS. FINANCIAL COUNSELORS WORK WITH PATIENTS AND INSURANCE COMPANIES INCLUDING MEDICARE AND MEDICAID TO HELP THE PATIENTS TO ACCESS SERVICES. THOSE WHO DO NOT QUALIFY FOR PUBLICLY AVAILABLE HEALTH INSURANCE, OR WHO ARE UNABLE TO PAY THEIR PORTION OF FEES ABOVE INSURANCE REIMBURSEMENT, MAY OBTAIN HELP THROUGH THE INSTITUTION'S FAP IF THEY ARE ELIGIBLE. THE PREMISE OF THE PROGRAM IS THAT ALL PATIENTS ARE EXPECTED TO CONTRIBUTE TO THEIR CARE BASED ON THEIR FINANCIAL ABILITY. THE FAP EMPLOYS SEVERAL STRATEGIES TO INCREASE PATIENTS' AWARENESS OF THE PROGRAM. DURING THE REGISTRATION PROCESS, FINANCIAL INTERVIEWERS EDUCATE PATIENTS ON THE VARIOUS PROGRAMS AVAILABLE TO THEM, INCLUDING GOVERNMENTAL PROGRAMS AND THE FINANCIAL ASSISTANCE PROGRAMS. MSK PERSONNEL SENDS THE FAP BROCHURE WITH THE INITIAL HOSPITAL BILL TO EVERY NEW PATIENT TO MAKE THEM AWARE OF THE CHARITY CARE/FINANCIAL ASSISTANCE PROGRAM. THE FAP IS ALSO MENTIONED IN EVERY STATEMENT AND LETTER THAT SENT TO A PATIENT. MOREOVER, THE FAP IS AGAIN MENTIONED IN EVERY COLLECTION LETTER SENT TO PATIENTS BY THE COLLECTION AGENCIES. EVEN AFTER A PATIENT'S ACCOUNT IS SENT TO COLLECTIONS, HE/SHE CAN STILL APPLY FOR FINANCIAL ASSISTANCE. IT IS NEVER TOO LATE TO APPLY FOR FINANCIAL ASSISTANCE AND RETROACTIVE FAP COVERAGE WOULD BE GIVEN IF A PATIENT IS DETERMINED ELIGIBLE FOR ASSISTANCE. INFORMATION ABOUT THE FINANCIAL ASSISTANCE PROGRAM IS ALSO AVAILABLE ON THE INSTITUTION'S WEBSITE AT WWW.MSKCC.ORG/FINANCIAL-ASSISTANCE OR BY CALLING OUR DEDICATED FINANCIAL ASSISTANCE LINE AT (212) 639-3810. PART VI, LINE 4 MSK'S INPATIENT HOSPITAL IS IN MID-MANHATTAN WITH ADDITIONAL OUTPATIENT TREATMENT CENTERS IN BROOKLYN, LONG ISLAND, WESTCHESTER COUNTY, AND NEW JERSEY. OUR PRIMARY CATCHMENT AREA ENCOMPASSES 23 COUNTIES ACROSS THE FIVE BOROUGHS OF NEW YORK CITY, LONG ISLAND, SOUTHERN NEW YORK STATE, NEW JERSEY, AND SOUTHWESTERN CONNECTICUT. A TOTAL OF 214,342 PATIENTS WERE SEEN AT MSK'S FACILITIES IN 2022, INCLUDING 194,242 (90.6 PERCENT) PATIENTS FROM THE TRI-STATE AREA (NY, NJ, CT); 19,010 (8.9 PERCENT) PATIENTS FROM OTHER PARTS OF THE UNITED STATES; AND 1,090 (0.5 PERCENT) PATIENTS FROM OTHER COUNTRIES. THESE PATIENTS ACCOUNTED FOR 24,113 ADMISSIONS TO OUR HOSPITAL WITH 170,076 RELATED PATIENT DAYS AND 686,000 OUTPATIENT VISITS AT OUR COMBINED FACILITIES IN NEW YORK CITY AND THE REGION. PART VI, LINE 5 AT MSK, WE ARE UNITED BY A SINGULAR VISION - ENDING CANCER FOR LIFE. OUR SPECIALIZED CARE TEAMS PROVIDE PERSONALIZED, COMPASSIONATE, EXPERT CARE TO PATIENTS OF ALL AGES. INFORMED BY BASIC RESEARCH DONE AT OUR SLOAN KETTERING INSTITUTE, SCIENTISTS ACROSS MSK COLLABORATE TO CONDUCT INNOVATIVE TRANSLATIONAL AND CLINICAL RESEARCH THAT IS DRIVING A REVOLUTION IN OUR UNDERSTANDING OF CANCER AS A DISEASE AND IMPROVING THE ABILITY TO PREVENT, DIAGNOSE, AND TREAT IT. MSK IS DEDICATED TO TRAINING THE NEXT GENERATION OF SCIENTISTS AND CLINICIANS, WHO GO ON TO PURSUE OUR MISSION AT MSK AND AROUND THE GLOBE. ONE OF THE WORLD'S MOST RESPECTED COMPREHENSIVE CENTERS DEVOTED EXCLUSIVELY TO CANCER, WE HAVE BEEN RECOGNIZED AS ONE OF THE TOP TWO CANCER HOSPITALS IN THE COUNTRY BY U.S. NEWS & WORLD REPORT FOR MORE THAN 30 YEARS. WE ARE NOT JUST CAREGIVERS, BUT THE CAREGIVERS WHO MAKE THE DIFFERENCE IN THE DARKEST HOURS. WE PROVIDE MULTIDISCIPLINARY CARE, WHERE EXPERTS FROM MANY FIELDS OF MEDICINE COME TOGETHER TO DEVELOP THE BEST TREATMENTS FOR INDIVIDUAL PATIENTS AND FOR THE TREATMENT OF PATIENTS WITH ALL TYPES OF CANCER. THIS HAS ALLOWED US TO BE AT THE FOREFRONT OF DEVELOPING TREATMENTS THAT ARE MORE EFFECTIVE AT TREATING CANCER, WHILE AT THE SAME TIME SPARING MANY PATIENTS FROM THE MOST SERIOUS SIDE EFFECTS OF TREATMENT. HAVING THE SCIENTISTS WHO ASK AND ANSWER THE TOUGHEST QUESTIONS, OUR BASIC AND TRANSLATIONAL RESEARCHERS HAVE MADE MANY SIGNIFICANT CONTRIBUTIONS TO THE SCIENTIFIC COMMUNITY'S UNDERSTANDING OF CANCER BIOLOGY AND CANCER GENETICS AS WELL AS TO RELATED FIELDS OF CELL BIOLOGY, MOLECULAR BIOLOGY, STRUCTURAL BIOLOGY, DEVELOPMENTAL BIOLOGY, MOLECULAR PHARMACOLOGY AND CHEMISTRY, IMMUNOLOGY, COMPUTATIONAL BIOLOGY, AND DRUG DEVELOPMENT. GENES FIRST IDENTIFIED IN OUR LABORATORIES ARE NOW THE FOCUS OF INTENSE RESEARCH IN OTHER LABORATORIES AROUND THE WORLD. DRUGS, MONOCLONAL ANTIBODIES, AND OTHER AGENTS FIRST DEVELOPED IN OUR LABORATORIES HAVE GONE ON TO GAIN REGULATORY APPROVAL FOR TREATING PATIENTS WORLDWIDE. RECENT EXPANSION OF OUR LABORATORY SPACE HAS ALLOWED US TO GROW OUR RESEARCH EFFORTS SO THAT GOING FORWARD WE CAN CONTINUE TO MAKE DISCOVERIES THAT WILL CHANGE THE WAY THE WORLD UNDERSTANDS CANCER AND AID IN THE DEVELOPMENT OF BETTER TREATMENTS FOR CANCER PATIENTS EVERYWHERE. IN 2022, MSK SPENT $755.90M IN SUPPORT OF ITS RESEARCH MISSION, OF WHICH $241.20M WAS SPONSORED BY GOVERNMENTAL AND OTHER NON-PROFIT ORGANIZATIONS, $154.82M FROM PHILANTHROPY, AND $359.63M FROM THE INSTITUTION'S FUNDS. TRAINING THE NEXT GENERATION IS AN IMPORTANT EXAMPLE OF HOW THE INSTITUTION MAKES CONTRIBUTIONS TO THE CARE AND TREATMENT OF CANCER PATIENTS FAR BEYOND ITS OWN WALLS THROUGH WORKFORCE DEVELOPMENT. OUR TRAINING, GRADUATE, AND CONTINUING EDUCATION PROGRAMS PREPARE PHYSICIANS, SCIENTISTS, NURSES, AND TECHNICIANS TO BE LEADERS IN THEIR CHOSEN FIELDS. THESE HEALTHCARE PROVIDERS CAN THEN TAKE THE EXPERTISE GAINED FROM WORKING WITH OUR SPECIALISTS TO OTHER HEALTHCARE INSTITUTIONS AROUND THE COUNTRY AND THROUGHOUT THE WORLD. MSK ALSO TRAINS GRADUATE STUDENTS AND POSTDOCTORAL RESEARCHERS WORKING IN MANY AREAS OF BASIC SCIENCE AND TRANSLATIONAL RESEARCH. WHEN THESE YOUNG SCIENTISTS COMPLETE THEIR TRAINING, THEY BRING THE SKILLS OBTAINED IN OUR LABORATORIES INTO THE ACADEMIC COMMUNITY AT LARGE AS WELL AS THE PRIVATE SECTOR. MSK SPONSORS SEVERAL PROGRAMS THAT GIVE MEDICAL STUDENTS, UNDERGRADUATES, AND HIGH SCHOOL STUDENTS THE OPPORTUNITY TO WORK AT THE INSTITUTION DOING CLINICAL AND LABORATORY RESEARCH. THROUGH THESE PROGRAMS, MSK STRIVES TO INCREASE THE PIPELINE OF SCIENTISTS AND PHYSICIANS WORKING IN ONCOLOGY. IN 2020, THE ORGANIZATION ESTABLISHED THE OFFICE OF HEALTH EQUITY (OHE) TO ADDRESS CANCER DISPARITIES THAT EXIST DUE TO RACIAL, ETHNIC, CULTURAL, OR SOCIOECONOMIC BARRIERS. THROUGH A PATIENT CENTRIC FOCUS, THE OHE IS RESPONSIBLE FOR LEADING PATIENT CARE AND RESEARCH ACTIVITIES INCLUDING THE CANCER HEALTH EQUITY RESEARCH PROGRAM (CHERP) AND CANCER EQUITY PROGRAMS. INTEGRAL TO OHE'S ROLE IS THE DEVELOPMENT OF HEALTH EQUITY RESEARCH AND EDUCATION AND TRAINING. AS SUCH THE OHE HAS IMPLEMENTED RECRUITING AND TRAINING INITIATIVES ACROSS THE INSTITUTION. THE OBJECTIVE OF THESE TRAINING PROGRAMS IS TO ENHANCE THE DIVERSITY OF FUTURE CANCER RESEARCH WORKFORCE BY PROVIDING UNDERREPRESENTED STUDENTS IN MEDICINE WITH EXPOSURE TO CUTTING-EDGE CANCER RESEARCH WITH RENOWNED MENTORS. THE RESEARCH PROGRAM IS FOCUSED ON HAVING DIVERSE POPULATIONS MORE EQUALLY REPRESENTED IN CANCER CLINICAL RESEARCH AND DEVELOPING A BETTER UNDERSTANDING OF THE DIFFERENCES IN CANCER INCIDENCE AND CANCER OUTCOMES EXPERIENCED BY GROUPS TRADITIONALLY UNDERREPRESENTED IN CLINICAL RESEARCH. THE OHE RESEARCH PROGRAM IS ALSO FOCUSED ON INCREASING ENROLLMENT OF UNDERREPRESENTED GROUPS ONTO CLINICAL TRIALS AT MSK. THE OHE PROVIDES FUNDING FOR THESE PROGRAMS ALLOWING UNDERREPRESENTED GROUPS IN MEDICINE OPPORTUNITIES TO PARTICIPATE IN THE NATIONAL CANCER INSTITUTE'S MEDICAL STUDENTS SUMMER PIPELINE PROGRAM. THE OHE ALSO COORDINATES A SIX-WEEK SUMMER EXPOSURE PROGRAM TO EXPOSE HIGH SCHOOL STUDENTS FROM UNDERSERVED COMMUNITIES TO CAREERS IN MEDICINE AND RESEARCH. MEMORIAL SLOAN KETTERING UTILIZED $237.09M OF THE INSTITUTION'S RESOURCES DURING 2022 TO SUPPORT ITS EDUCATION AND TRAINING MISSION, WHICH WE CONSIDER VITAL, GIVEN OUR LEADERSHIP ROLE IN CANCER CARE TREATMENT AND RESEARCH. $55.71M OF THE AMOUNT WAS SPONSORED BY GOVERNMENTAL AND OTHER REVENUE SOURCES AND $181.38M FROM THE INSTITUTION'S GENERAL FUND. THE INSTITUTION HAS A BOARD FOR EACH OF THE SEVEN ENTITIES. AS OUTLINED IN SCHEDULE O, THERE IS A TOTAL OF 116 BOARD MEMBERS. MANY ARE MEMBERS OF MORE THAN ONE ENTITY'S BOARD AND THEREFORE ARE COUNTED MORE THAN ONCE. THE GOVERNING BODY IS COMPRISED OF INDEPENDENT BOARD MEMBERS FROM THROUGHOUT THE UNITED STATES. MSK DOES NOT EXTEND MEDICAL STAFF PRIVILEGES TO COMMUNITY-BASED PHYSICIANS. ALL PHYSICIANS ARE ON STAFF AND ARE EMPLOYEES OF MSK, WITH LIMITED EXCEPTIONS. IN ITS PURSUIT TO FURTHER IMPROVE PATIENT CARE, MEDICAL EDUCATION, AND RESEARCH, THE INSTITUTION REINVESTS ANY SURPLUS FUNDS IN THE INSTITUTION'S POOL OF RESERVES. THESE RESERVES GENERATE INCOME TO SUPPORT FUTURE OPERATIONS AND RESTRICTED FUND SPENDING. BY PROVIDING true AMERICAN CANCER SOCIETY 3380 CHASTAIN MEADOW PKY KENNESAW GA 30144 131788491 501c(3) 80000 CANCER AWARENESS LEUKEMIA & LYMPHOMA SOCIETY 3 INTERNATIONAL DR RYE BROOK NY 10573 135644916 501c(3) 50000 CANCER AWARENESS SUSAN G KOMEN FOR THE CURE 901 E ST NW WASHINGTON DC DC 20004 751835298 501c(3) 27000 CANCER AWARENESS LONG ISLAND NETS 168 39TH STREET BROOKLYN NY 11232 222219916 15000 CANCER AWARENESS GILDA'S CLUB WESTCHESTER 80 MAPLE AVE WHITE PLAINS NY 10601 133939823 501c(3) 8000 CANCER AWARENESS HARLEM SKYSCRAPER CYCLING CLASSIC 18 MOUNT MORRIS PARK W NY NY 10027 501C(3) 10000 CANCER AWARENESS STIPENDS 394 17816000 Form 990, Schedule I FOR THE YEAR 2022, THE AMOUNT IS FOR STIPENDS PAID TO 183 RESEARCH FELLOWS AND 211 GRADUATE SCHOOL STUDENTS. EDUCATION AND TRAINING INCLUDE CLASSROOM INSTRUCTION WITH HANDS-ON EXPERIENCE IN BOTH RESEARCH LABORATORIES AND CLINICAL CARE ACTIVITIES. THE AFOREMENTIONED GRANTEES ARE REQUIRED TO BE IN COMPLIANCE WITH ACADEMIC REQUIREMENTS. THIS INCLUDES DIRECT SUPERVISION AND DIRECTION BY PHYSICIANS AND RESEARCH INVESTIGATORS. X X true true X X X X X true true false false false false false true true true CRAIG B THOMPSON MD PRESIDENT & CEO-UNTIL 9/22 1786111 6080000 48739 15250 190860 8120960 16000 JASON KLEIN SVP CHIEF INVESTMENT OFFICER 1178244 2530000 3099681 24400 51722 6884047 16000 MARK BILSKY MD ATTENDING-NEUROSURGERY 1827832 1500000 24038 24400 35726 3411996 8000 BABAK MEHRARA MD CHIEF ATTENDING-SURGERY 2614193 100000 57755 24400 49219 2845567 8000 MICHAEL HARRINGTON EVP & CFO 1532483 1171000 39797 24400 34595 2802275 8000 JULIO GARCIA AGUILAR MD CHIEF ATTENDING-SURGERY 1643890 1050000 34003 24400 49226 2801519 8000 JEFFREY DREBIN MD CHAIRMAN ATTENDNING-SURGERY 2452681 200000 69211 24400 51344 2797636 8000 KATHRYN MARTIN EVP & COO 1525357 861318 46861 24400 48553 2506489 16000 MARTIN WEISER MD ATTENDING-SURGERY 1318932 1023077 58304 24400 52931 2477644 8000 LISA DEANGELIS MD PHYSICAN IN CHIEF 1360618 763848 28620 24400 47482 2224968 8000 SIMON POWELL MD DIRECTOR MSKCC PROTON, INC. 1386898 455364 140636 24400 36812 2044110 8000 JOAN MASSAGUE PHD DIRECTOR 1102204 520030 177656 24400 45864 1870154 8000 KENNETH MANOTTI SVP DEVELOPMENT 950559 541062 39006 24400 41602 1596629 8000 JORGE LOPEZ ESQ EVP GENERAL COUNSEL 1016197 481555 20227 24400 52496 1594875 8000 SELWYN VICKERS MD PRESIDENT & CEO EFF 9/22 862205 500000 4158 15250 43802 1425415 0 ROXANNE TAYLOR SVP CHIEF MKT/COMM UNTIL 10/22 708790 450000 200238 24400 7994 1391422 6415 DEBRA BERNS ESQ SVP CHIEF RISK OFFICER 899983 360000 13690 24400 19331 1317404 8000 KERRY BESSEY SVP CHIEF HR OFFICER 752352 429270 43312 24400 52020 1301354 16000 FREDERICK GROVES EVP HOSPITAL ADMINISTRATION 679171 322290 54445 24400 36343 1116649 8000 REMY EVARD EVP & CHIEF DIGIT OFF EFF 1/22 795472 100000 78902 16202 35854 1026430 0 MARK SVENNINGSON SVP FINANCE 736994 175003 32685 24400 36566 1005648 16000 ERIN MCDONOUGH SVP CH MKT/COMM OFF EFF 10/22 712670 50000 5291 24400 16944 809305 0 CAROLYN LEVINE ESQ DEPUTY GEN COUNSEL 464068 89116 17868 15250 31787 618089 7780 AMADOR CENTENO SVP REAL ESTATE DEVLP EFF 7/22 347732 0 35073 24034 1592 408431 0 MARGARET BURKE DIRECTOR, MSKCC PROTON, INC. 563177 216500 51538 24400 52082 907697 16000 Supplemental Compensation Information SCHEDULE J, PART I, LINE 1A BUSINESS OR FIRST-CLASS TRAVEL IS ALLOWED FOR FLIGHTS GREATER THAN SIX CONTINUOUS HOURS FOR ANY EMPLOYEE NOT FUNDED BY FEDERAL GRANTS. EXCEPTIONS TO THE SIX HOUR RULE ARE REVIEWED ON AN INDIVIDUAL BASIS. ALL TRAVEL MUST BE APPROVED BEFORE ANY ARRANGEMENTS ARE MADE. MSKCC HAS AN ACCOUNTABLE TRAVEL POLICY AND THEREFORE, DOES NOT INCLUDE TRAVEL AS TAXABLE COMPENSATION. THE INSTITUTION REQUIRES THE PRESIDENT TO BE ON CALL AND TO PERFORM DUTIES AS AND WHEN APPROPRIATE DURING OFF-DUTY PERIODS AS WELL AS DURING NORMAL OFFICE HOURS. AN EMPLOYMENT CONTRACT REQUIRES OUR PRESIDENT TO LIVE IN THE OFFICIAL RESIDENCE OWNED AND MAINTAINED BY THE INSTITUTION. THE CONTRACT REQUIRES OUR PRESIDENT TO USE THE RESIDENCE FOR INSTITUTIONAL PURPOSES, INCLUDING, BUT NOT LIMITED TO, MEETINGS WITH STAFF, DONORS AND POTENTIAL DONORS, VISITING PROFESSORS AND SCIENTISTS, AND OTHER PERSONS INVOLVED WITH THE AFFAIRS OF THE INSTITUTION, CONFIDENTIAL INTERVIEWS WITH MEMBERS AND PROSPECTIVE MEMBERS OF THE STAFF; AND FOR OTHER INSTITUTIONAL ACTIVITIES CONDUCTED DURING AND OUTSIDE OF NORMAL OFFICE HOURS. THE COST IS REPORTED AS COMPENSATION ON FORM 990 AND IS EXCLUDED FROM TAXABLE COMPENSATION IN ACCORDANCE WITH CODE SECTION 119. SCHEDULE J, PART I LINE 4A - INCLUDED IN FORM 990 IS SEVERANCE PAY: PHILLIP KANTOFF MD., CHAIRMAN ATTENDING $1,250,040 TERMINATED IN 2021. ROXANNE TAYLOR, SVP, CHIEF MARKETING & COMMUNICATIONS OFFICER $179,567 TERMINATED 2022 LINE 4b-INCLUDED IN FORM 990: JASON KLEIN WAS PAID $2,980,253 AS PART OF A DEFERRED COMPENSATION AGREEMENT. LINE 7 - INCENTIVE PAY IS PROVIDED TO OFFICERS AND KEY EMPLOYEES BASED ON THEIR ACHIEVEMENT OF PRE-DETERMINED GOALS RELATING TO QUALITY OF CARE, PATIENT SAFETY, OPERATIONAL EFFICIENCY AND FINANCIAL PERFORMANCE. THE COMPENSATION COMMITTEE OF THE BOARD AUTHORIZES ALL EXECUTIVE BONUSES AND INCENTIVE PLANS ON AN ANNUAL BASIS. LINE 8 - AN EMPLOYMENT CONTRACT WAS ENTERED INTO AND SIGNED PRIOR TO EMPLOYMENT. A DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 6499063Z7 2013-06-28 80000000 SEE PART VI false false false B DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 000000000 2016-04-28 110000000 SEE PART VI false false false C NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY 222045817 000000000 2016-09-09 145000000 SEE PART VI false false false D DOMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 000000000 2017-12-20 335567386 SEE PART VI false false false A 74000000 0 80000000 0 0 0 0 0 0 0 80000000 0 2013 true false true true B 18702374 0 110239999 0 0 0 155282 0 0 110009717 75000 0 2017 false false true true C 76125000 0 145000000 0 0 0 72861 0 0 144627139 300000 0 2018 false false true true D 11550000 0 339194534 0 0 0 2262236 0 0 245499309 91432989 0 2019 true false true true A false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true B false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true C false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true D false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true A false false false true false false 0 false 0 false true B false false false true false false 0 false 0 false true C false false false true false false 0 false 0 false true D false false false true false false 0 false 0 false true A true B true C true D true PART I, COLUMN (F) DESCRIPTION OF PURPOSE 2013 SERIES BONDS (DASNY)- CUSIP #6499063Z7: 2013 SERIES BONDS WERE USED TO CURRENT REFUND THE 2010 SERIES BONDS ISSUED 9/2/2010. 2016 SERIES BONDS (DASNY) - CUSIP #000000000: 2016 SERIES BONDS WERE USED TO CONSTRUCT/RENOVATE AND UPGRADE AND EQUIP VARIOUS FACILITIES. 2016 SERIES BONDS (NJEDA) - CUSIP #000000000: 2016 SERIES BONDS WERE USED TO CONSTRUCT AND EQUIP VARIOUS FACILITIES. 2017 SERIES BONDS (DASNY)- CUSIP #000000000: 2017 SERIES BONDS WERE USED TO CURRENT REFUND THE 2015 SERIES BONDS ISSUED JULY 16, 2015 AND CONSTRUCT VARIOUS FACILITIES. 2019 SERIES BONDS (DASNY) - CUSIP #64990GVG4: 2019 SERIES BONDS WERE USED TO REIMBURSE EXPENDITURES INCURRED TO CONSTRUCT A PATIENT CARE FACILITY. 2022 SERIES #1 BONDS (DASNY) - CUSIP #65000BPS1: 2022 SERIES #1 BONDS WERE USED TO RENOVATE VARIOUS LOCATIONS - HOSPITAL AND OUTPATIENT FACILITIES AND REPLACE MACHINERY EQUIPMENT. 2022 SERIES #2 BONDS (DASNY) - CUSIP #000000000: 2022 SERIES #2 BONDS WERE USED TO RENOVATE NON-PATIENT SPACE. PART II LINE 3 - THE AMOUNT OF PROCEEDS ON PART II LINE 3 IS DIFFERENT FROM PART I COLUMN (E) BECAUSE PART II LINE 3 INCLUDES INVESTMENT INCOME AND GAINS/LOSSES. PART III LINE 3(D) - ANY MANAGEMENT CONTRACTS AND RESEARCH AGREEMENTS THAT MAY RESULT IN PRIVATE BUSINESS USE OF BONDS FINANCED PROPERTIES ARE REVIEWED FIRST BY IN-HOUSE STAFF WHO ARE KNOWLEDGEABLE OF AND RESPONSIBLE FOR THE FORM 990. OUTSIDE COUNSEL IS CONSULTED IF QUESTIONS ARISE. PART IV LINE 2(C) THE DASNY 2013 SERIES BONDS REBATE CALCULATIONS WERE LAST PERFORMED ON JUNE 21, 2019. THE DASNY 2016 SERIES BONDS REBATE CALCULATIONS WERE PERFORMED ON MAY 19, 2023. THE NJEDA 2016 SERIES BONDS REBATE CALCULATIONS WERE PERFORMED ON JULY 6, 2022. THE DASNY 2017 SERIES BONDS REBATE CALCULATIONS WERE PERFORMED ON MARCH 17, 2023. A DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 64990GVG4 2019-11-01 342248699 SEE PART VI false false false B Dormitory Authority of the State of New York 146000293 65000BPS1 2022-06-28 199996589 SEE PART VI false false false C Dormitory Authority of the State of New York 146000293 000000000 2022-08-01 100000000 SEE PART VI false false false A 0 0 342248699 0 0 0 2248699 0 0 340000000 0 0 2019 false false true true B 0 0 200507663 0 0 0 1220622 0 0 199162041 125000 0 2022 false false true true C 0 0 101054264 0 0 0 227400 0 0 23057369 15000 77754495 false false false true A false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true B false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true C false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true A false true false false false false 0 false 0 false true B false true false false false false 0 false 0 false true C false true false false false false 0 false 0 false true A true B true C true DR T LINDSTEN SEE PART V BELOW 318446 FAMILY EMPLOYMENT false MEMORIAL MEDICAL CARE PC SEE PART V 541000 MANAGEMENT AGREEMENT false JESSICA STUART SEE PART V 21411 FAMILY EMPLOYMENT false Business transactions with interested parties 1. DR. CRAIG THOMPSON WAS THE PRESIDENT OF THE INSTITUTION UNTIL SEPTEMBER 2022. HIS SPOUSE, DR. TULLIA LINDSTEN, IS A LABORATORY MEMBER FOR SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH. HER COMPENSATION, FOR 2022 WAS $318,446 2. DR. LISA DEANGELIS IS THE PHYSICIAN-IN -CHIEF OF THE ORGANIZATION. IN SUCH A CAPACITY, SHE IS A 75% OWNER OF MEMORIAL MEDICAL CARE PC (MMPC). MMPC IS A SECTION 501(C)(3) TAX-EXEMPT CAPTIVE MEDICAL GROUP. MMPC OPERATES A FACILITY IN BROOKLYN WHERE PATIENTS HAVE ACCESS TO A WIDE RANGE OF SERVICES, INCLUDING ADVANCED IMAGING, STATE-OF THE-ART THERAPIES, CUTTING-EDGE CLINICAL TRIALS, AND A MULTIDISCIPLINARY TEAM OF SPECIALISTS. THE AMOUNT REPORTED IN PART IV, $541,000, IS THE NET COSTS FOR SUCH SERVICES IN 2022. 3. SCOTT STUART IS A BOARD MEMBER OF MEMORIAL HOSPITAL, HIS DAUGHTER, JESSICA STUART, IS AN INSTRUCTOR AT MEMORIAL HOSPITAL. HER COMPENSATION FOR 2022 WAS $21,411 THE INDIVIDUALS LISTED WERE NOT A PARTY TO THE TRANSACTIONS. THERE IS NO SHARING OF THE INSTITUTE'S REVENUE. THE PURCHASE OF GOODS AND SERVICES BY THE INSTITUTION WERE MADE IN THE ORDINARY COURSE OF THE PROVIDER'S BUSINESS, AT COMMERCIALLY AVAILABLE RATES NORMALLY CHARGED TO OTHERS X 173 12032474 MARKET VALUE false true true PART I PUBLICLY TRADED DONATED STOCK IS SOLD BY MERRILL LYNCH ON BEHALF OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATED ORGANIZATIONS. LINE 9 (B) NUMBER OF CONTRIBUTUINS PART VI, LINE 2 FOR THE TAX YEAR 2022, THE FOLLOWING BUSINESS RELATIONSHIPS WERE REPORTED: 1. DIRECTORS ELLEN V. FUTTER AND PETER J. SOLOMON 2. DIRECTORS ELLEN V. FUTTER AND RICHARD I. BEATTIE PART VI, LINES 6-7 THE ARTICLES OF INCORPORATION AND BY-LAWS WERE REVIEWED TO DETERMINE THAT THE SUPPORTED ORGANIZATIONS OUTLINED IN SCHEDULE-A HAVE THE POWER TO ELECT OR APPOINT MEMBERS TO THE BOARD OF THE SUPPORTING ORGANIZATIONS. MEMORIAL SLOAN-KETTERING CANCER CENTER, EIN 13-1924236, (MSK), IS THE SINGLE MEMBER OF THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM LLC, PCCTC, WHICH HAS ELECTED TO BE TREATED AS A DISREGARDED ENTITY OF MSK FOR TAX PURPOSES AND MSKCC PROTON, INC. WHICH IS ALSO TREATED AS A CORPORATION FOR TAX PURPOSES. MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES EIN 13-1624082, (MEM), IS THE SINGLE MEMBER OF MSKCC PROPERTIES LLC, WHO HAS ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. PART VI, LINE 11B PRIOR TO FILING THE RETURN, A REVIEW OF THE 990 WAS CONDUCTED BY THE SR. VP OF FINANCE AND THE CHIEF FINANCIAL OFFICER. IT IS THEN PRESENTED TO, AND REVIEWED BY, THE JOINT AUDIT COMMITTEE OF THE BOARD. THE JOINT AUDIT COMMITTEE REFERS THE FORM 990 TO THE FULL BOARD, AND A COPY IS PROVIDED TO EACH BOARD MEMBER FOR FURTHER REVIEW. MEMORIAL SLOAN-KETTERING'S FORM 990 IS REVIEWED BY COUNSEL AND IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. PART VI, LINE 12C In 2022, MSK's conflict of interest (COI) program was implemented through three comprehensive policies for Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases and Sloan-Kettering Institute for Cancer Research, which are outlined below: 1. Conflict of Interest and Commitment Policy (the "Individual COI Policy"). a. The Individual COI Policy applied to: (i) physicians and scientists with academic appointments at any level; (ii) any clinical provider who could independently write orders or prescriptions; (iii) individuals whose roles included the design, conduct or reporting of research and/or were engaged in human subject research; (iv) administrative employees with independent authority to make purchasing decisions or who were otherwise able to bind, negotiate on behalf, or execute agreements on behalf of, MSK; and (v) individuals that served on MSK institutional committees with responsibility for oversight of research, formulary, or purchasing decisions. b. MSK's Compliance COI Office ("Compliance") and the institutional conflict of interest committee (the "MSK COI Committee") were responsible for the administration of this policy, under the oversight of the committee of the Board (the "Board COI Committee") dedicated exclusively to discharging the Board's responsibility and authority over MSK's conflicts of interest program. c. Upon becoming covered by the Individual COI Policy, annually thereafter and/or as new significant interests arose, an individual was required to disclose financial interests and external relationships and activities ("interests"), whether paid or unpaid, that reasonably appeared to be related to the individual's institutional responsibilities. Covered Persons were required to disclose interests for themselves and immediate family members. d. Depending on the circumstances and based on established criteria, disclosed interests were reviewed by Compliance, the MSK COI Committee, MSK COI Committee designee(s), and/or the Board COI Committee to determine whether an individual conflict of interest existed or presented the perception thereof (i.e. whether an individual financial interest could directly and significantly impact an individual's institutional responsibilities, or an individual's interest could be directly and significantly impacted by their institutional responsibilities). e. The policy required any individual conflict of interest to be managed, reduced or eliminated. When a conflict of interest determination was made, the MSK COI Committee, the MSK COI Committee designee(s), or the Board COI Committee, as applicable, determined how to address it. For those conflicts deemed manageable, management strategies implemented included disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; recusal and/or other limitation on role; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of an individual's interest. 2. Institutional Conflict of Interest Policy (the "Institutional COI Policy"). a. The Institutional COI Policy applied to financial interests and relationships ("interests") held by MSK as an institution, as well as those financial interests and relationships ("interests") held by five senior executive officers deemed "Institutional Officials,their immediate family members. Institutional Officials included the President and Chief Executive Officer, the Physician-In-Chief and Chief Medical Officer, the Chief Operating Officer, the Chief Financial Officer, and the Director of the Sloan-Kettering Institute for Cancer Research. b. Institutional interests held by MSK were made available to Compliance through regular reports from and ongoing engagement with relevant MSK departments. Institutional interests held by Institutional Officials were disclosed through the process described above in the Individual COI Policy, as well as the process described below in the Board COI Policy. c. The MSK COI Committee or MSK COI Committee designee(s) were responsible for determining whether an institutional conflict of interest existed; i.e. whether the institutional interest held by MSK or an Institutional Official (or their immediate family members) could, or could reasonably be perceived to, directly and significantly affect the design, conduct, reporting, review, or oversight of MSK research or the outcome of an MSK activity or decision. d. The policy required any institutional conflict of interest to be managed, reduced or eliminated. When an institutional conflict of interest determination was made, the MSK COI Committee and/or the MSK COI Committee designee(s) determined how to address it. For those conflicts deemed manageable, management strategies implemented included recusal of the applicable Institutional Official from decision-making regarding the arrangement and disclosure to relevant personnel; disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of MSK's or an Institutional Official's institutional interest. 3. Boards of Governing Trustees Conflict of Interest Policy (the "Board COI Policy"). a. The Board COI Policy applied to Board members, officers, and other MSK senior leadership. Individuals covered by the Board COI Policy were required to disclose financial interests and relationships, as defined by the policy, annually and on an ongoing basis. Other entities in the same tax-exempt group had overlapping officers and Board members as described in Schedule O; such persons reported financial interests through this or related processes. b. The Board COI Committee was responsible for determining whether any interest disclosed under the Board COI Policy gave rise to a conflict of interest. The policy required that the members of the Board COI Committee vote, without the individual with the potential conflict present, to determine whether a conflict of interest existed. All members participating in the vote were required to be disinterested with respect to the transaction, arrangement, or relationship. c. The covered individual with the conflict of interest could make a presentation to the Board COI Committee, but could not participate in or influence the discussion of, or vote on, the proposed transaction, arrangement, or relationship. The existence and resolution of any conflict of interest, along with associated determinations made and votes taken, were required to be documented in writing. d. For any transaction, arrangement, or relationship that involved a conflict of interest, a conflict management plan could be implemented if doing so was in the best interests of MSK. Management plans could require disclosure, recusal or other limitation of role, independent oversight and confidentiality. PART VI, LINE 15 MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC) IS COMMITTED TO ENSURING THAT ITS EXECUTIVE COMPENSATION PROGRAM ADHERES TO THE ESTABLISHED STANDARDS OF REGULATORY COMPLIANCE AND BEST CORPORATE GOVERNANCE. THE MSKCC BOARD OF TRUSTEES AND GOVERNING TRUSTEES HAS CHARGED THE JOINT HUMAN RESOURCES COMMITTEE (WHICH IS COMPOSED ENTIRELY OF INDEPENDENT BOARD MEMBERS WITH NO CONFLICTS OF INTEREST IN REGARD TO EXECUTIVE COMPENSATION) WITH MAKING ALL DECISIONS RELATED TO COMPENSATION FOR OFFICERS AND KEY EMPLOYEES. THE COMMITTEE REVIEWS THE TOTAL COMPENSATION OF THE INDIVIDUALS, INCLUDING BOTH CURRENT AND DEFERRED COMPENSATION, AND ALL EMPLOYEE BENEFITS, ON AN ANNUAL BASIS TO ENSURE THAT THE TOTAL COMPENSATION OF EACH OFFICER AND KEY EMPLOYEE IS REASONABLE. TO ASSIST IN THE COMPLETION OF ITS RESPONSIBILITIES, THE COMMITTEE ENGAGES THE SERVICES OF A NATIONALLY RECOGNIZED CONSULTING FIRM SPECIALIZING IN EXECUTIVE COMPENSATION FOR NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS. EACH YEAR THE COMMITTEE REVIEWS A COMPREHENSIVE REPORT PREPARED BY THE FIRM THAT INCLUDES MARKET DATA FOR FUNCTIONALLY COMPARABLE ROLES IN COMPARABLE ORGANIZATIONS (I.E., NOT-FOR-PROFIT ACADEMIC/RESEARCH MEDICAL CENTERS, ESPECIALLY THOSE SHARING A MISSION SIMILAR TO MSKCC, WITH OTHER HEALTHCARE SECTORS CONSIDERED ON A SELECTED BASIS) AND SUMMARIZES THE RELATIVE MARKET POSITION OF EACH EXECUTIVE'S TOTAL COMPENSATION. THE LAST REVIEW WAS MARCH 2022, WHICH SET THE COMPENSATION FOR THE PERIOD APRIL 2022 TO MARCH 2023. ADDITIONALLY, A SENIOR MEMBER OF THE CONSULTING FIRM ATTENDS COMMITTEE MEETINGS TO PROVIDE INFORMATION AND TO RESPOND TO QUESTIONS BY THE MEMBERS OF THE COMMITTEE. COMPENSATION LEVELS ARE ESTABLISHED CONSIDERING THE MARKET DATA, AN ASSESSMENT OF PERFORMANCE, AND OTHER BUSINESS JUDGMENT FACTORS, CONSISTENT WITH MSKCC'S EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE'S DECISIONS ARE MADE IN THE BEST INTERESTS OF MSKCC AND ARE INTENDED TO ENSURE THE RECRUITMENT AND RETENTION OF KEY EXECUTIVE TALENT, CONSISTENT WITH THE MARKET PRACTICES OF OTHER NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS OF COMPARABLE SCOPE, MISSION AND COMPLEXITY. THE COMMITTEE'S REVIEW PROCESS FOLLOWS THE INTERMEDIATE SANCTIONS GUIDELINES FOR QUALIFYING FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE OF 1986: - THE COMPENSATION ARRANGEMENT IS APPROVED IN ADVANCE BY AN "AUTHORIZED BODY" OF THE APPLICABLE TAX EXEMPT ORGANIZATION (I.E, THE COMMITTEE, WHICH IS COMPOSED ENTIRELY OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITHIN THE MEANING OF THE REGULATIONS UNDER SECTION 4958). - THE AUTHORIZED BODY OBTAINS AND RELIES UPON "APPROPRIATE DATA AS TO COMPARABILITY" PRIOR TO MAKING ITS DETERMINATION, FOR WHICH COMPARABILITY DATA ARE PROVIDED AND ANALYZED BY SULLIVAN, COTTER AND ASSOCIATES, INC., A WELL-REGARDED EXPERT IN THE AREA OF HEALTHCARE COMPENSATION. - THE COMMITTEE ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION CONCURRENTLY WITH MAKING THAT DETERMINATION, AGAIN AS REQUIRED IN THE REGULATIONS. PART VI, LINE 19 THE INSTITUTION HAS ENGAGED DAC BOND AS OUR INVESTOR RELATIONS AND DISCLOSURE/DISSEMINATION AGENT. COPIES OF OUR IRS FORM 990, 990T AND OUR AUDITED FINANCIAL STATEMENTS, QUARTERLY UNAUDITED FINANCIAL STATEMENTS, AND THE BOND OFFERING STATEMENTS FOR ALL OUR DEBT ISSUES ARE AVAILABLE ON THEIR WEB ADDRESS: WWW.DACBOND.COM. THE CONFLICT OF INTEREST AND COMMITMENT POLICY IS ACCESSIBLE ON OUR INSTITUTIONAL WEB SITE: WWW.MSKCC.ORG. HOWEVER, OUR GOVERNING DOCUMENTS SUCH AS THE ARTICLES OF INCORPORATION AND CORPORATE BY-LAWS ARE NOT AVAILABLE FOR PUBLIC INFORMATION. PART VII, SECTION A THIS IRS FORM 990 IS FILED UNDER GROUP EXEMPTION NUMBER 3475, EIN 91-2154267. THE ATTACHED LIST REPRESENTS MEMBERS FROM THE GOVERNING BOARDS OF THE FOLLOWING AFFILIATED INSTITUTIONS THAT MAKE UP OUR EXEMPT GROUP: MEMORIAL SLOAN-KETTERING CANCER CENTER (MSK) EIN 13-1924236, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (MEM) EIN 13-1624082, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (SKI) EIN 13-1624182, S.K.I. REALTY, INC. (SKR) EIN 13-3389586, LOUIS V. GERSTNER JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES (SKG) EIN 20-2212588, MSK INSURANCE US, INC. (MVI) EIN 83-0363317, AND MSKCC PROTON INC.,(MPI) EIN 35-2397819. ALSO INCLUDED IN THE GROUP IS MSK PROPERTIES LLC. EIN 35-2464610 WITH MEMORIAL HOSPITAL BEING THE SOLE MEMBER. MEMORIAL SLOAN KETTERING BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK, VICE CHAIR OF THE BOARD (A) STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS, VICE CHAIR OF THE BOARD JAMIE C. NICHOLLS, VICE CHAIR OF THE BOARD (B) JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D. SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART, CHAIR OF THE BOARD CRAIG B. THOMPSON, M.D., BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER. EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (C) SELWYN M VICKERS, M.D., PHD, BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER. EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (D) DOUGLAS A. WARNER III, HONORARY CHAIR OF THE BOARD PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS MEMORIAL HOSPITAL BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE, HONORARY CHAIRMAN OF THE BOARD IAN COOK, CHAIR OF THE BOARD (A) STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS JAMIE C. NICHOLLS, CHAIR OF THE BOARD (B) JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D. SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (C) SELWYN M VICKERS, MD,PHD, BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (D) DOUGLAS A. WARNER III PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS SLOAN KETTERING INSTITUTE BOARD OF GOVERNING TRUSTEES: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON HENRY A. FERNANDEZ WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR., HONORARY CHAIR OF THE BOARD JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. WILLIAM HELMAN MARGARET KEANE MARIE-JOSEE KRAVIS, CHAIR OF THE BOARD JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY ALAN D SCHNITZER STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (C) SELWYN M VICKERS, MD, PHD. BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (D) DOUGLAS A. WARNER III PETER A. WEINBERG 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS S.K.I. REALTY BOARD OF DIRECTORS: RICHARD I. BEATTIE LOUIS V. GERSTNER, JR. JAMES G. NIVEN, PRESIDENT CLIFTON S. ROBBINS SCOTT M. STUART, CHAIRMAN OF THE BOARD DOUGLAS A. WARNER III 6 TOTAL BOARD MEMBERS 6 INDEPENDENT BOARD MEMBERS GERSTNER GRADUATE SCHOOL BOARD OF TRUSTEES: RICHARD I. BEATTIE ELLEN V. FUTTER LOUIS V. GERSTNER, JR., CHAIR EMERITUS (A) MARIE-JOSEE KRAVIS ALAN D SCHNITZER, CHAIR OF THE BOARD (A) SCOTT M. STUART CRAIG B. THOMPSON, M.D. BOARD MEMBER, PRESIDENT, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (C) SELWYN M VICKERS MD, PHD, BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER (D) DOUGLAS A. WARNER III (A) 8 TOTAL BOARD MEMBERS 7 INDEPENDENT BOARD MEMBERS MSK INSURANCE U.S. BOARD OF DIRECTORS: DEBRA BERNS, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER KATHRYN MARTIN, DIRECTOR AND SECRETARY, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER STEPHEN C. SHERRILL, CHAIRMAN OF THE BOARD MARK SVENNINGSON, BOARD MEMBER AND PRESIDENT, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER JEFFREY P. JOHNSON, BOARD MEMBER AND VICE PRESIDENT MICHAEL P HARRINGTON, EMPLOYEE, NOT AN INDEPENDENT BOARD MEMBER 6 TOTAL BOARD MEMBERS 2 INDEPENDENT BOARD MEMBERS MSKCC PROTON INC., BOARD OF DIRECTORS: SIMON POWELL MD., EMPLOYEE, NOT AN INDEPENDENT DIRECTOR MICHAEL HARRINGTON, EMPLOYEE, NOT AN INDEPENDENT DIRECTOR MARGARET BURKE, EMPLOYEE, NOT AN INDEPENDENT DIRECTOR 3 TOTAL DIRECTOR, 0 INDEPENDENT DIRECTORS (A) EFFECTIVE JUNE 2022 (B) UNTIL JUNE 2022 (C) UNTIL OCTOBER 2022 (D) EFFECTIVE OCTOBER 2022 PART VII, SECTION B AMOUNTS PAID TO INDEPENDENT CONTRACTORS INCLUDE AMOUNTS PAID TO SUBCONTRACTORS AS WELL AS REIMBURSABLE EXPENSES. PART XI RECONCILIATION OF NET ASSETS, OTHER NON-OPERATING (EXPENSE): CHANGE IN POSTRETIREMENT $ 140,114,000 OTHER NON-OPER EXPENSE (10,379,000) TOTAL $ 129,735,000 PROSTATE CANCER CLINICAL TRIALS 1275 YORK AVE NEW YORK NY 10065 352506225 CANCER CARE DE 19074000 3149000 MSKCC MEMORIAL MEDICAL CARE PC 1275 YORK AVENUE NEW YORK NY 10065 352491455 CANCER CARE NY 501(C)3 10 MSKCC true TRI-INSTITUTIONAL THERAPEUTICS DISC INST 1300 YORK AVE NEW YORK NY 10065 463673346 MED RESEA EDU DE 509(A)(3) 12E N/A true MEM INFECT DISEASE 1275 YORK AVE NY NY 10065 133278582 HEALTH CARE NY MEM RELATED 2816016 0 false 0 true 1.00000 MEM MEDICAL CONSULT 1275 YORK AVE NY NY 10065 133278550 HEALTH CARE NY MEM RELATED 10868351 0 false 0 true 1.00000 MEM SOLID TUMOR GRP 1275 YORK AVE NY NY 10065 133278578 HEALTH CARE NY MEM RELATED 47704965 0 false 0 true 1.00000 MEM PULMONARY FUNC 1275 YORK AVE NY NY 10065 133304834 HEALTH CARE NY MEM RELATED 4928298 0 false 0 true 1.00000 MEM CARDIOPULMONARY 1275 YORK AVE NY NY 10065 133278552 HEALTH CARE NY MEM RELATED 5623677 0 false 0 true 1.00000 MSK RADIOLOGY GRP 1275 YORK AVE NY NY 10065 133375559 HEALTH CARE NY MEM RELATED 78255556 0 false 0 true 1.00000 MEM NUCLEAR MED 1275 YORK AVE NY NY 10065 133278580 HEALTH CARE NY MEM RELATED 10018171 0 false 0 true 1.00000 MEM RADIATION ONCOL 1275 YORK AVE NY NY 10065 133237927 HEALTH CARE NY MEM RELATED 25887511 0 false 0 true 1.00000 MEM PATHOLOGY GRP 1275 YORK AVE NY NY 10065 133365998 HEALTH CARE NY MEM RELATED 57379205 0 false 0 true 1.00000 MEM ANESTHESIOLOGY 1275 YORK AVE NY NY 10065 133367135 HEALTH CARE NY MEM RELATED 67418786 0 false 0 true 1.00000 MEM PEDIATRICS GRP 1275 YORK AVE NY NY 10065 133346908 HEALTH CARE NY MEM RELATED 10352522 0 false 0 true 1.00000 MEM NEUROLOGY GRP 1275 YORK AVE NY NY 10065 133399377 HEALTH CARE NY MEM RELATED 14662023 0 false 0 true 1.00000 MEM PSYCHIATRY GRP 1275 YORK AVE NY NY 10065 133430629 HEALTH CARE NY MEM RELATED 4019852 0 false 0 true 1.00000 MSK SURGERY GROUP 1275 YORK AVE NY NY 10065 134010372 HEALTH CARE NY MEM RELATED 184940977 0 false 0 true 1.00000 MSK HAUPPAUGE 1275 YORK AVENUE NY NY 10065 134059247 HEALTH CARE NY MEM RELATED 5772737 0 false 0 true 1.00000 INTEGRATIVE MED 1275 YORK AVE NY NY 10065 542092060 HEALTH CARE NY MEM RELATED 2240274 0 false 0 true 1.00000 MSK-REGIONAL NETWK 1275 YORK AVENUE NY NY 10065 020594889 HEALTH CARE NY MEM RELATED 22732574 0 false 0 true 1.00000 MSK BASKING RIDGE 1275 YORK AVENUE NY NY 10065 593801080 HEALTH CARE NY MEM RELATED 19043156 0 false 0 true 1.00000 MEM URGENT CARE GRP 1275 YORK AVE NY NY 10065 651263291 HEALTH CARE NY MEM RELATED 7893695 0 false 0 true 1.00000 MEM CLN GENETICS 1275 YORK AVE NY NY 10065 651263292 HEALTH CARE NY MEM RELATED 910042 0 false 0 true 1.00000 MEM DEVELOP CHEMO 1275 YORK AVE NY NY 10065 133278548 HEALTH CARE NY MEM RELATED 5811207 0 false 0 true 1.00000 MSK CLINIC PRACTICE 1275 YORK AVE NY NY 10065 510616510 HEALTH CARE NY MEM RELATED 12570136 0 false 0 true 1.00000 MEM CLINICAL PHY 1275 YORK AVE NY NY 10065 133278556 HEALTH CARE NY MEM RELATED 2126700 0 false 0 true 1.00000 MEM DERMATOLOGY GRP 1275 YORK AVE NY NY 10065 133278581 HEALTH CARE NY MEM RELATED 8590503 0 false 0 true 1.00000 MEM ENDOCRINE GRP 1275 YORK AVE NY NY 10065 133278583 HEALTH CARE NY MEM RELATED 4754474 0 false 0 true 1.00000 GASTROENTEROLOGY 1275 YORK AVE NY NY 10065 133278574 HEALTH CARE NY MEM RELATED 10182130 0 false 0 true 1.00000 MEM HEMATOLOGYLYMP 1275 YORK AVE NY NY 10065 133278575 HEALTH CARE NY MEM RELATED 22938805 0 false 0 true 1.00000 MSK HARRISON 1275 YORK AVENUE NY NY 10065 300831483 HEALTH CARE NY MEM RELATED 29190150 0 false 0 true 1.00000 MSK BERGEN 1275 YORK AVENUE NY NY 10065 611791803 HEALTH CARE NY MEM RELATED 17647019 0 false 0 true 1.00000 MSK MONMOUTH 1275 YORK AVE NY NY 10065 300937486 HEALTH CARE NY MEM RELATED 26584674 0 false 0 true 1.00000 MSK NASSAU 1275 YORK AVENUE NY NY 10065 611904151 health care NY MEM RELATED 18624955 0 false 0 true 1.00000 RALPH LAUREN CENTER 1275 YORK AVENUE NY NY 10065 320577172 health care NY MEM RELATED 439483 0 false 0 true 1.00000 PANAKEIA ENERGY 10000 MEMORIAL DR HOUSTON TX 77024 800891961 INVESTMENT DE MSK EXCLUDED UNDER 512 -19664 0 false false BTS LIQUIDATING LLC 1430 BROADWAY NY NY 10018 262602952 INVESTMWNT NY MSK EXCLUDED UNDER 512 -76775 129602 false 0 false 0.80000 CHARITABLE REMAINDER TRUSTS 196 N/A TWO SIGMA US ALL CAP EQUITY BATA CAYMEN 89 NEXUS WAY CAMANA BAY GRAND CAYMAN CJ KY1-9007 INVESTMENT CJ MSK C AXAR OFFSHORE FUND LTD PO BOX 309 UGLAND HOUSE GRAND CAYMAN CJ CJ KY1-1104 INVESTMENT CJ MSK c false false false false false false false false false false false false false false true false false MEMORIAL MEDICAL CARE PC Q 541000 Cost